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Abstract 
 
Obesity is a worldwide health problem due to its epidemic proportions and high risk for 
other metabolic disorders, such type 2 diabetes, cardiovascular diseases and certain 
cancers. It is generally accepted that a chronic low-grade inflammatory state is at the 
pathogenic core of obesity. High-fat diet-induced obesity features of hyperleptinemia, 
hyperinsulinemia, fat deposition, glucose intolerance, central and peripheral 
inflammation, as well as central and peripheral leptin resistance and hypothalamic leptin 
signaling compromised. Obesity also features of the impairment of prefrontal cortex, and 
impairment of leptin-induced regulation of brain-derived neurotrophic factor (BDNF) 
expression and synaptogenesis, which has been considered to be associated with the 
incidence of neuronal degenerative diseases, cognitive decline, and depression. Some 
plant-derived triterpene saponins are anti-inflammatory and inhibit the NF-κB signaling. 
Those triterpene saponins are potential therapeutic agents for the obesity-associated 
inflammation to be determined. Natural extracted triterpene saponins, ginsenoside Rb1 
and teasaponin, are used in this PhD research project. Ginsenoside Rb1, extracted from 
Ginseng, has anti-inflammation effect and anti-obesity effect. However, it is unclear 
whether it has the effect of anti-obesity-associated inflammation and whether it can 
address the above listed features issue of obesity. Teasaponin is an active compound of 
tea extract, has been demonstrated to ameliorate obesity, reduce inflammation and 
improve central leptin sensitivity in obese mice in our previous study. Tea consumption 
improves cognition and increases brain activation in the prefrontal cortex. However, little 
is known on the ability of teasaponin on recognition memory and its effect on leptin 
signaling in the prefrontal cortex of high-fat diet-induced obese mice. 
The aim of Chapter 2 was to investigate the effects of ginsenoside Rb1 on treating 
obesity, obesity-associated inflammation and central leptin resistance, as well as 
hypothalamic leptin signaling. Results demonstrated that ginsenoside Rb1 treatment 
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reduced food intake, prevented body weight gain and fat deposition, improved glucose 
tolerance, as well as improved hyperleptinemia in high-fat diet-induced obese mice. 
Furthermore, ginsenoside Rb1 treatment reduced obesity-associated peripheral 
inflammation and hypothalamic inflammation, indicating by the decrease expression of 
TNFα, IL-6, IL-1β and pIKK. Ginsenoside Rb1 treatment also decreased the protein 
expression of SOCS3 and PTP1B, the negative regulators of leptin signaling. The 
reduced central inflammation and downregulation of SOCS3 and PTP1B by Rb1 
treatment, contributed to the improvement of central leptin resistance and restore leptin 
signaling in the mediobasal hypothalamus of obese mice treated with Rb1. Reduced 
peripheral inflammation contributed to the improvement of glucose intolerance. Besides, 
the increased expression of circulating PYY, and hypothalamic POMC upregulation and 
AgRP downregulation extend the mechanism on suppressing food intake by Rb1.  
The aim of chapter 3 was to examine the effects of ginsenosdie Rb1 on central leptin 
effects on BDNF expression and synaptogenesis in the prefrontal cortex during obesity 
via an in vivo and an in vitro model. Ginsenoside Rb1 chronic treatment improved central 
leptin sensitivity, leptin-JAK2-STAT3 signaling and leptin-induced regulation of BDNF 
expression in the prefrontal cortex of high-fat diet induced obese mice. In cultured 
prefrontal cortical neurons, palmitic acid, the saturated fat, impaired leptin-induced 
BDNF expression, reduced the immunoreactivity and mRNA expression of synaptic 
proteins, and impaired leptin-induced neurite outgrowth and synaptogenesis. Importantly, 
Rb1 significantly prevented these pernicious effects induced by palmitic acid. These 
results indicate that Rb1 reverses central leptin resistance and improves leptin-BDNF-
neurite outgrowth and synaptogenesis in the prefrontal cortical neurons. 
The aim of chapter 4 was to evaluate the effects of teasaponin on recognition memory 
and leptin signaling in the prefrontal cortex of obese mice, and on leptin effects on 
neurogenesis in the saturated fatty acid, palmitic acid, treated primary cortical neurons. 
Oral teasaponin treatment significantly improved memory deficit in high-fat diet (HFD) 
fed mice assessed by the novel object recognition test. Furthermore, teasaponin treatment 
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(10mg/kg, intraperitoneal) for 21 days improved downstream leptin signaling (JAK2, and 
STAT3), and leptin’s effect on BDNF, in the prefrontal cortex of HFD fed mice. In the in 
vitro study, teasaponin reversed the impairment caused by palmitic acid on the leptin-
mediated BDNF expression, leptin-mediated neurite outgrowth (MAP2 mRNA, neurite 
branching and length), and synaptogenesis (PSD95 expression). These results indicate 
teasaponin improves obesity associated recognition memory deficit and central leptin 
effects on BDNF, neurite outgrowth and synaptogenesis in the prefrontal cortex. 
In conclusion, this thesis demonstrated two natural triterpene saponins, ginsenoside Rb1 
and teasaponin, as the potential therapeutic agents for obesity and obesity-associated 
neuronal degenerative diseases, cognitive decline, and depression. Those therapeutic 
effects benefit from the properties of these two triterpene saponin targeting on anti-
obesity-associated inflammation, positive regulation of central leptin signaling, and 
reversal of central leptin resistance. Overall, both ginsenoside Rb1 and teasaponin 
supplementation may be used to treat obesity, and prevent obesity-associated 
neurodegeneration and improve cognitive function. 
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CHAPTER ONE 
1.1 Introduction 
The prevalence of obesity is a worldwide health problem, which affects one third of the 
world’s population (Hruby and Hu, 2015; Ng et al., 2014; Stevens et al., 2012) and 
causes great economic burden (Hruby and Hu, 2015). It is an important risk factor for the 
development of type 2 diabetes, cardiovascular disease, and certain cancer, as well as 
depression, and neurodegenerative diseases(Hruby and Hu, 2015). Increasing evidence 
indicated that a chronic low-grade inflammatory state during obesity is the core 
pathogenic of obesity and type 2 diabetes (Cai et al., 2005; Lumeng and Saltiel, 2011).  
The pro-inflammatory response includes elevated pro-inflammatory, such as tumor 
necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and interleukin 1 beta (IL-1β),  and 
activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
signaling pathway, including inhibitor kappa B alpha (IκBα) and IκB kinase (IKK) 
(Osborn and Olefsky, 2012; Thaler et al., 2012). The activation of pro-inflammatory 
cytokines and NF-κB signaling pathway induce insulin and leptin resistance in the 
peripheral tissue and the central nervous system (Hayden and Ghosh, 2008; Zabolotny et 
al., 2002; Zhang et al., 2008). Obesity-associated inflammation in the liver and white 
adipose tissue leads glucose intolerance, insulin resistance and metabolic dysfunction 
(Cai et al., 2005; Stanton et al., 2011b; Xu et al., 2003). Over-nutrition and obesity also 
leads to hypothalamic inflammation, which results in the central leptin resistance, hepatic 
insulin resistance, a reduction in thermogenesis, and cardiovascular disorders (Arruda et 
al., 2011; Cai and Liu, 2011; Thaler et al., 2010; Thaler and Schwartz, 2010; Wisse and 
Schwartz, 2009). Therefore, to treat obesity and metabolic syndrome, it is quite necessary 
to block peripheral and central inflammation.  Furthermore, obesity impairs prefrontal 
cortex, which is a major regulatory center for cognitive function (Frith and Dolan, 1996; 
Le et al., 2006). Obesity impairs leptin-induced regulation of BDNF expression, neurite 
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outgrowth and synaptogenesis, which has been considered to be associated with the 
incidence of neuronal degenerative diseases, cognitive decline, and depression (Gupta et 
al., 2013; Vanevski and Xu, 2013; Zuccato and Cattaneo, 2009). Hence, it is essential to 
attenuate the obesity-associated impairment of cortical leptin-BDNF, neurite outgrowth 
and synaptogenesis to prevent the risk of development obesity-associated metabolic 
disorder and neurodegeneration. 
Studies showed that some triterpene saponins are naturally derived inhibitors of NFκB 
signaling and have anti-inflammatory potential (Salminen et al., 2008b).Triterpene 
saponin ginsenoside Rb1, one of the active compounds extracted from ginseng, has been 
reported to have anti-inflammation effect, anti-obesity effect and neuroprotective effect 
(Kim et al., 2014; Li et al., 2011b; Lin et al., 2013; Liu et al., 2011a; Nam et al., 2013; 
Wang et al., 2008; Xiong et al., 2010; Xue et al., 2006; Yuan et al., 2007).  Reports also 
indicated, tea and tea extract (including teasaponin) has anti-inflammatory effect (Park et 
al., 2011; Ren et al., 2018). However, it is unknown whether Rb1 can improve obesity-
associated inflammation and leptin resistance, and also unknown the effects of Rb1 on 
leptin-BDNF, neurite outgrowth. It is also unclear the effects of teasaponin on obesity-
associated leptin resistance, leptin-BDNF-neurite outgrowth and neurogenesis, as well as 
obesity-associated recognition impairment. The present PhD series studies were designed 
to investigate the chronic treatment effects of Rb1 on body weight change, energy intake, 
obesity-associated peripheral and hypothalamic inflammation, glucose intolerance and 
central leptin resistance, cortical leptin sensitivity and synaptogenesis of high-fat diet-
induced obese mice, as well as effects of teasaponin on obesity-linked recognition 
impairment and cortical leptin sensitivity. These series PhD studies will provide new 
potential anti-obesity therapeutic agents that modulate obesity-associated inflammation, 
central leptin sensitivity and prevent obesity-associated neurodegeneration.   
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1.2 Literature Review 
1.2.1 Obesity  
The prevalence of overweight and obesity has been reached the worldwide epidemic 
proportion. In 2013, the proportion of overweight and obese adults increased to 36.9% in 
men, and 38% in women worldwide; the proportion of overweight and obese children and 
adolescents in developed countries increased to 23.8% in boys and 22.6% in girls (Ng et 
al., 2014). As the established health risks and the substantial globally increase in 
prevalence, obesity has become a major global health challenge and a heavy burden on 
financial of health care systems worldwide. Globally, it is estimated that overweight and 
obesity caused 3.4 million deaths, 3.9% of the years of life lost and 3.8% of disability-
adjusted life-years in 2010 (Ng et al., 2014). In Australia, about 27% of children and 
adolescents and 63% of adults were overweight or obese in 2014-2015(AIHW, 2017). In 
Australia in 2011, 7% of the total health burden was attributed to overweight and obesity, 
63% of which was fatal burden. It is estimated that obesity has cost $8.6 billion of the 
Australian economy in 2011-2012(AIHW, 2017). Also, obesity leads to higher likelihood 
of chronic diseases such as  cardiovascular disease, type 2 Diabetes Mellitus, stoke, 
osteoarthritis, respiratory, sleep problems, hypertension and certain types of cancers 
(Dakin et al., 2004; Daling et al., 2001; Huang and Chen, 2009). The issue of obesity will 
lead to both increased mortality and morbidity (Frezza, 2004; Kojima et al., 2009). 
Therefore, due to the medical complication and the associated tremendous economic 
consequences, the alarming growth rate undeniably makes obesity an urgent and critical 
issue to be addressed (Devlin et al., 2000; Marx, 2003; Wisse et al., 2007). 
Obesity results from a sustained energy imbalance—when the energy intake is greater 
than energy expenditure. It can be attributed by both genetic predisposition and lifestyle 
factors such as overconsumption of high energy density diet, sedentary lifestyles and 
reduction in physical activity (Brown et al., 2009; Challis et al., 2003; Hill and Peters, 
1998; Perusse and Bouchard, 2000). Epidemiological studies have shown that the 
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consumption of high-fat diets is positively associated with body weight gain and obesity 
in human population (Bray and Popkin, 1998; Koegler et al., 1999; Macdiarmid et al., 
1996; Smyth and Heron, 2006).  
 
1.2.2 Dietary fat consumption and high-fat diet-induced obese mouse model 
Excessive energy intake by overconsumption of diet that rich in saturated fat contributes 
to energy imbalance and weight gain, leading to overweight and obesity (Brooks et al., 
2013; Hill et al., 2000). In a human study, a diet with >35% energy as fat, is classified as 
a high-fat diet (HFD), and promotes body weight gain both in men and women (Donnelly 
et al., 2008). Strong evidence suggests greater intake of energy-enrich diet is associated 
with bigger body fat mass among children and higher body weight among adults (AIHW, 
2017). Therefore, to address the obesity issue, high-fat diet is used to establish high-fat 
diet-induced obesity (DIO) animal models to mimic the most common cause of obesity in 
humans.  
In a DIO mouse model, the development of chronic high-fat diet-induced obesity is a 
progressive process varying in energy intake, body weight gain and leptin sensitivities at 
different stages. It can be divided into Early Response (Stage1-DIO, < 5 wks), Middle 
Regulatory (Stage 2-DIO, from 5 to 15 wks), and Late Failure (Stage 3-DIO, > 15 wks) 
Stages (Lin et al., 2000b). It can be summarized as in the early stage the body responds to 
high-fat diet, while in the middle stage the body tries to prevent excessive fat stores by 
activation of its regulatory system, and finally chronic consumption of high-fat diet 
eventually fails the regulatory system and results in obesity (Table 1). In parallel with 
these whole-body measures of energy balance, our lab have further demonstrated as well 
the progressive dysregulation of leptin secretion, peripheral and then central leptin 
insensitivity, central leptin receptor gene expression, and the downstream 
neurotransmitter expressions (Table 1).  
The impairment of the potential molecular pathways behind the central nerves system, 
which may links to the dysregulation of food intake and body weight, may mainly 
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attribute to the development of DIO and related leptin insensitivities. This study used the 
DIO mouse model to address the metabolic disorders. 
Table1.1. Characteristics of three stages of diet-induced obesity 
 Early stage 
(week 1) 
Middle stage  
(week 8) 
Late stage  
(week 19) 
Reference 
Body weight ND ↑11% ↑30% (Lin et al., 2000b) 
Energy intake ↑Slightly (ND) ↓16% ↑15% (Lin et al., 2000a) 
RVB ND ↑45% ↑84% (Lin et al., 2000a) 
Leptin 
sensitivity 
2ug/g i.p. Yes No No (Lin et al., 2000b) 
0.1ug/g icv Yes Yes No 
Arc LR mRNA ND ↑ ↑ (Huang et al., 
2003a; Huang et 
al., 2003b; Lin et 
al., 2000a) 
POMC mRNA ND or ↑  
 (2 weeks) 
ND  ↓ (Huang et al., 
2003a; Huang et 
al., 2003b; Lin et 
al., 2000a; 
Ziotopoulou et al., 
2000) 
NPY mRNA ND or ↓ 
 (2days) 
↓    ↑ (Huang et al., 
2003a; Huang et 
al., 2003b; Lin et 
al., 2000a; 
Ziotopoulou et al., 
2000) 
AgRP ↓(2days) ↓ ↓ (Huang et al., 
2003a; Huang et 
al., 2003b; 
Ziotopoulou et al., 
2000) 
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conclusion Response to 
high-energy diet 
with slight 
hyperphagia 
Compensatory  
attempts to limit 
excessive fat stores 
by activation of 
regulatory system 
Failure of 
regulatory 
systems with 
ensuing rapid fat 
accumulation 
 
     ND: no statistical difference; RVB: ratio of visceral fat (mg)/body weight (g); LR: leptin 
receptor;      POMC: proopiomelanocortin; NPY: neuropeptide Y; AgRP: agouti related-protein  
 
1.2.3 Leptin signaling and central leptin resistance 
1.2.3.1 Leptin and leptin signaling 
Leptin, a 16 kDa peptide hormone consisting of 167 amino acid residues, is produced by 
adipocytes in proportion to fat stores. Accumulating evidences show that leptin acts on 
brain to regulate energy balance via activating leptin receptor and related signaling 
(Bjorbaek and Kahn, 2004; Fruhbeck, 2006). Leptin receptors, members of the class I 
cytokine receptor family, exert its function through JAKs (Janus kinases) and STATs 
(signal transducers and activators of transcription). Leptin receptor b, the full-length 
isoform, is considered to be the functional receptor to activate the JAK/STAT signal 
transduction pathway (Fruhbeck, 2006). It is clear that leptin receptor b is highly 
expressed in multi-regions of hypothalamus, especially in the arcuate nucleus of 
the hypothalamus (Arc) area (Bjorbaek and Kahn, 2004). The ARC region contains two 
key populations of neurons, NPY and POMC neurons, which produce orexigenic 
peptides and anorectic peptides, respectively (Cone, 2005). Leptin has been reported to 
modulate the activity of both neurons, inducing the inhibition of NPY/AgRP mRNA 
expression and the elevation of POMC mRNA expression (Enriori et al., 2006). In 
addition, leptin activates leptin receptor b signaling in hypothalamus, including 
JAK2/STAT3 and insulin receptor substrate/ phosphoinositide 3-kinase/protein kinase B 
(IRS/PI3K/Akt), to regulate the feeding behavior (Hill et al., 2008; Sahu, 2004; Wauman 
and Tavernier, 2011). Additionally, AMP-activated protein kinase (AMPK), fuel-sensing 
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signaling has been suggested to involve in the regulation of leptin’s anorectic effect 
(Blanco Martinez de Morentin et al., 2011; Gao et al., 2007; Morris and Rui, 2009). 
Leptin receptor is also distributed in other regions of the brain, such as hippocampus and 
prefrontal cortex (Ates et al., 2014). Recently, leptin-STAT3 has been reported to be 
involved in the neuroprotection of cerebral ischemia via promoting neuronal survival in 
vitro and in vivo (Amantea et al., 2011; Tang, 2008). Leptin signaling in the 
hypothalamic and prefrontal cortex in obese were investigated in this PhD study. 
 
1.2.3.2 Central leptin resistance and its underlying mechanism  
It is well recognized that adequate circulating leptin provides a signal of energy stores to 
central nervous system (CNS), enable the brain to adjust energy balance via suppressing 
food intake and increasing the energy expenditure (Bates and Myers, 2003; Friedman and 
Halaas, 1998). Conversely, lack of leptin signaling, such as attributing to mutation of 
leptin (ob/ob mice) or leptin receptor (db/db mice) in rodents or human, leads to 
hyperphagia and suppression of energy expenditure accompanied by increased expression 
and secretion of orexigenic peptides (NPY and AgRP) (Ahima et al., 1996; Bates and 
Myers, 2003; Lord et al., 1998). However, most obese humans and rodents do not have 
lower circulating leptin. In fact, they usually have extremely high level of plasma leptin, 
which still fails to reduce food intake and body weight and fails to increase energy 
expenditure, showing the resistance to leptin effect. 
The definition of leptin resistance is characterized by the failure of elevated circulating 
leptin to suppress feeding and weight gain which in turn exacerbates  obesity in general 
(Enriori et al., 2006; Myers et al., 2008b). Recently researches produced a high-fat diet-
induced obesity (DIO) model in several strains of rodents focusing on the issue of leptin 
resistance (Hariri and Thibault, 2010; Howard et al., 2004; Judge et al., 2008; Levin and 
Dunn-Meynell, 2002; Lin et al., 2000b; Metlakunta et al., 2008). The development of 
high-fat diet-induced obesity and leptin resistance in C57BL/6J mice can be divided into 
3 stages: early stage, middle stage and late stage. In the early stage, mice on HFD gain 
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weight and remain response to peripheral leptin injection. In the middle stage, mice 
elevate plasma leptin and fails to response to peripheral leptin but still sensitive to central 
leptin administration. Finally, in the late stage, DIO mice with highly increasing body 
adiposity and extreme high level of plasma leptin show central leptin resistance, failing to 
suppress food intake and body weight in response to icv leptin administration (Lin et al., 
2000b).  
Interestingly, Protein Tyrosine Phosphatase 1B (PTP1B), a cellular protein, has been shown 
to implicate in the regulation of cellular leptin signaling. PTP1B dephosphorylates JAK2, 
the initial tyrosine kinase mediating leptin signaling. Neuronal PTP1B knockout mice 
have reduced body weight, food intake and enhanced leptin sensitivity (Bence et al., 
2006). Furthermore hypothalamic PTP1B is increased during HFD-induced leptin 
resistance (White et al., 2009). The i.p. injection of PTP1B inhibitor Trodusquemine 
(MSI-1436) decreased food intake and body weight in diet-induced obese mice (Lantz et 
al., 2010). These results suggest PTP1B plays an important role in central leptin 
insensitivity (Cheng et al., 2002; Myers et al., 2008b; Sahu, 2004).  
Additionally, low-grade pro-inflammatory is at the pathogenic core of obesity. The 
activation of pro-inflammatory cytokines and NF-κB signaling pathway mediate the 
transcription of the suppressor of cytokine signaling 3 (SOCS3) and PTP1B, which will 
induce insulin and leptin resistance in peripheral tissue and the central nervous system. 
To alleviate the central leptin resistance, study 1 was carried out to investigate the effect 
of chronic ginsenoside Rb1 treatment. Study 2 and study 3 were addressing leptin 
resistance issue in the prefrontal cortex caused by the saturated fat. 
 
1.2.4 Obesity-associated inflammation and its detrimental effects on leptin 
resistance and cognitive decline 
Chronic low-grade pro-inflammatory state is at the pathogenic core of obesity and type 2 
diabetes (Cai et al., 2005; Lumeng and Saltiel, 2011). This inflammatory response 
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includes elevated levels of pro-inflammatory cytokines, such as tumor necrosis factor 
alpha (TNF-α), interleukin 1 beta (IL-1β) and interleukin 6 (IL-6), and activation of the 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling 
pathway, including inhibitor kappa B alpha (IκBα) and IκB kinase (IKK) (Osborn and 
Olefsky, 2012; Thaler et al., 2012). The activation of pro-inflammatory cytokines and 
NF-κB signaling pathway mediate the transcription of the suppressor of cytokine 
signaling 3 (SOCS3) and protein-tyrosine phosphatase 1B (PTP1B), negative regulators 
of insulin and leptin signaling, which induce insulin and leptin resistance in peripheral 
tissues and the central nervous system (Hayden and Ghosh, 2008; Zabolotny et al., 2002; 
Zhang et al., 2008). Obesity associated inflammation in white adipose tissue and the liver 
leads to glucose intolerance, insulin resistance and metabolic dysfunction (Cai et al., 
2005; Stanton et al., 2011b; Xu et al., 2003). Over-nutrition and obesity also leads to 
hypothalamic inflammation and stimulation of local proinflammatory NF-κB signaling, 
resulting in the dysfunction of hypothalamic neurons (Thaler et al., 2012; Zhang et al., 
2008).  Furthermore, recent studies have shown that induction of inflammation in the 
hypothalamus results in experimental obesity, resistance to the anorexigenic hormone 
leptin, peripheral insulin resistance and defective regulation of food intake and energy 
expenditure (Arruda et al., 2011; Calegari et al., 2011; Milanski et al., 2012).   
Neuroinflammation in obesity could contribute to cognitive decline and dementia. Pro-
inflammatory cytokines, such as IL-6 and IL-1β have been reported to disrupt neural 
circuits involved in cognition and memory (Gemma and Bickford, 2007; Jankowsky and 
Patterson, 1999; Nguyen et al., 2014). For instance, juvenile HFD intake promotes LPS-
stimulated IL-1β and TNFα expression in the hippocampus, which is likely to be 
contributed to a selective impairment of consolidation that impaired long-term spatial 
memory but not short-term memory (Boitard et al., 2014a). Besides, in children, intake of 
saturated fatty acids impairs both relational and item memory (Nguyen et al., 
2014). Obesity-associated inflammation in hypothalamus and hippocampus has been 
reported (Arruda et al., 2011; Boitard et al., 2014a; Cai and Liu, 2011). While at this 
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stage the prefrontal cortex is to be investigated. As obesity-associated inflammation 
deleterious leptin resistance and neurodegeneration, it is valuable to pursuit therapeutic 
agents that have anti-obesity, anti-inflammation and alleviating neurodegenerative 
effects.      
 
1.2.5 BDNF and neurite outgrowth and synaptogenesis regulation by leptin 
Brain-derived neurotrophic factor (BDNF) plays an important role in neurite outgrowth 
(ie, elongation and branching), synaptic plasticity, synaptogenesis and the regulation of 
energy balance (Noble et al., 2011; Yu et al., 2009), through the activation of its receptor 
tropomyosin-related kinase B (TrkB). Aberrant BDNF/TrkB signaling is associated with 
obesity, cognitive impairment, and other neurodegenerative diseases (Gupta et al., 2013; 
Vanevski and Xu, 2013). Moreover, the BDNF gene mutation is associated with 
increasing early-onset obesity and cognitive impairment in BDNF-haploinsufficient 
patients (Gray et al., 2006). The BDNF protein level in the prefrontal cortex is decreased 
in rodents fed a chronic high-fat (HF) diet (Kanoski et al., 2007b). Furthermore, leptin, 
secreted from adipocytes, is a key regulator of BDNF expression in the hypothalamus 
(Liao et al., 2012) and brain stem (Bariohay et al., 2005a), promoting negative energy 
balance. Leptin increases hippocampic BDNF in normal mice, but not in diet-induced 
obese (DIO) mice, which exhibit depressive behaviour (Yamada et al., 2011), suggesting 
central leptin resistance in the obese mice. Thus the impairment of leptin-regulated 
BDNF in the prefrontal cortex by saturated fat may play an important role in central 
nervous system dysfunction in obese subjects. Improving leptin-regulated BDNF is 
imperative to improving obesity-associated brain dysfunction, including cognitive 
impairment. 
Leptin involves in the regulation of the cellular events including neurogenesis, axon 
growth, and synaptogenesis (Bouret, 2010). Leptin has been shown to regulate 
neurogenesis, such as increasing axonal growth cone size in cortical neurons (Valerio et 
al., 2006). Recently, leptin-STAT3 has been reported to be involved in the 
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neuroprotection of cerebral ischemia via promoting neuronal survival in vitro and in vivo 
(Amantea et al., 2011; Tang, 2008). It is known that leptin signaling molecules, JAK2 
and STAT3, distribute around the postsynaptic sites in the cerebral cortex (Murata et al., 
2000). An immunocytochemistry study also shows BDNF and TrkB lie in the 
postsynaptic densities in the cerebral cortex of adult rats (Aoki et al., 2000). These 
findings suggest that leptin-JAK2-STAT3 signaling and BDNF/TrkB might regulate 
synaptogenesis and synaptic plasticity in the prefrontal cortex. Study 2 and study 3 focus 
on the hypothesis that leptin will regulate BDNF, neuritegrowth and synaptogenesis in 
the prefrontal cortex. 
  
1.2.6 Obesity-associated impairment of prefrontal cortex and 
neurodegeneration 
Apart from hippocampus, the prefrontal cortex is another important brain region which 
regulates cognition. Impairment in the prefrontal cortex has been identified in obesity, 
mood disorders and neurodegenerative diseases. For example, obese women have a lower 
activation in the prefrontal cortex in response to a meal than lean women examined by 
positron emission tomography (Le et al., 2007). The abnormal structure and dysfunction 
in the prefrontal cortex is associated with depression and anxiety-like behaviours and 
Alzheimer’s disease (Drevets et al., 2008).Cross-sectional study on obesity and brain 
structure showed that higher levels of BMI were associated with lower global brain 
volume, and  dorsolateral prefrontal cortex (DLPFC) in obese individuals was 
preferentially vulnerable to atrophy (Bischof and Park, 2015; Brooks et al., 2013; Ward et 
al., 2005). 
Obesity is associated with the neurodegenerative diseases. It is reported that obese 
rodents induced by a high-saturated fat diet have cognitive impairment, depressive 
behaviour, and central leptin resistance (Farr et al., 2008; Kanoski and Davidson, 2011; 
Yamada et al., 2011). Alzheimer’s disease has been linked to a HFD and neuronal leptin 
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resistance (Bonda et al., 2014; Hanson et al., 2013). Overweight/obesity individuals at 
varying degrees of risk for bipolar disorder exhibit greater cognitive impairment 
(McIntyre et al., 2017). A cross-sectional study revealed early cognitive decline in the 
obese participants, indicated by their normal but significantly lower performance on 
attention and more impulsive compared to the normal weight participants (Cook et al., 
2017). Since obesity increase the neurodegeneration, the research on potential therapeutic 
agents to treat obesity-associated neurodegenerative disorders is quite essential.  
 
1.2.7 Triterpene saponins 
Plant triterpene saponins, biologically, are considered defensive compounds against 
pathogenic microbes and herbivores. These saponins also have beneficial properties for 
humans. For instance, Panax plant, well-known traditional herbal medicines, contains 
saponins (including ginsenosides) with various pharmacological effects (Sawai and Saito, 
2011; Shibata, 2001). Triterpene saponins are groups of pant secondary metabolites with 
structurally composed of a lipid soluble aglycone and a water soluble sugar residues 
(Abid Ali Khan et al., 2012). The amphiphilic nature of the triterpene saponins suggests 
that they intercalate into the cell membrane (Abid Ali Khan et al., 2012) to mediate the 
cellular events. Some plant-derived triterpene saponins are anti-inflammatory and inhibit 
the NF-κB signaling pathway (Salminen et al., 2008b).  
In this study, triterpene saponins ginsenoside Rb1 and teasaponin, derived from ginseng 
and tea respectively, were used on the animal models to treat obesity-associated 
metabolic dysfunctions, such as leptin resistance. 
 
1.2.7.1 Ginsenoside Rb1 
Ginseng, a traditional herbal medicine, is reported to be adaptogen that enhances body 
stability against physical loads, and is also suggested to improve cognitive function (Heo 
et al., 2011). Ginsenosides, the mainly active constituents that are found in extracts of 
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varies species of ginseng, attribute to the pharmacological properties of ginseng (Attele et 
al., 1999b). Ginsenoside Rb1 (Rb1) is one of the major bioactive components of ginseng 
saponins. It has been well chemically characterized, which has the structure of a 
tetracyclic triterpenoid with a molecular weight of 1109.26 and a molecular formula of 
C54H92O23 (Figure 1.1) (Cho et al., 2004). Rb1 has an amphiphilic nature that enables it to 
intercalate the plasma membrane, affect membrane function, and elicit a cellular response 
(Abid Ali Khan et al., 2012). This compound inhibits inflammation in in vitro and in vivo 
models, including anti-inflammatory effects on aortic smooth muscle exposed to TNF-α 
(Li et al., 2011a), the colon of mice with colitis (Joh et al., 2011), and brain tissue in an 
cerebral ischemia animal model (Zhu et al., 2012). Both human and animal studies have 
demonstrated various physiological effects of Ginsenosides in increasing satiety and 
improving glucose metabolism. Recent studies suggested that ginsenosides has 
anorexigenic effect and anti-obesity effect (Etou et al., 1988; Shang et al., 2008; Xiong et 
al., 2010). Rats acute intraperitoneal administrated of Rb1 (10mg/kg) significantly 
decreased food intake during 4-10 hours after treatment. Chronic treatment of Rb1 (ip) 
for 4 weeks significantly reduced food intake, body weight, plasma leptin, fasting glucose 
and hypothalamic NPY mRNA expression level in DIO rats after 13 weeks’ HFD 
feeding. Furthermore Rb1 (10µmol/L) treated on primary hypothalamic neurons activated 
Akt, leptin signaling, peaking at 3h after treatment (Xiong et al., 2010). Ginseng berry 
extract has been used to treat leptin receptor deficient obese mice (ob/ob), showing 
decreased food intake and body weight, reduced hyperglycemia and improved glucose 
intolerance (Attele et al., 2002). Similarly, the saponins of ginseng can inhibit food 
intake, decrease body weight and blood glucose and improve insulin sensitivity in diet-
induced obese rats and mice (Kim et al., 2005; Lin et al., 2013). Furthermore, oral 
administration of ginseng can increase insulin sensitivity and improve glucose intolerance 
in patients suffering Type 2 diabetes (Vuksan et al., 2008).  
Recent animal and cell models show that Rb1 has neuroprotective (Gao et al., 2010; Zhu 
et al., 2012) and anti-obesity effects (Xiong et al., 2010). For example, Rb1 increases 
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BDNF expression in rats with cerebral ischemia (Gao et al., 2010). Clinical data shows 
that ginseng treatment for 24 weeks improves cognitive function for up to 2 years in 
patients with Alzheimer’s disease (Heo et al., 2011).  
However, it is unknown whether Rb1 can improve obesity-associated inflammation, 
central leptin resistance and obesity-associated impairment of neurite outgrowth and 
synaptogenesis. Study 1 and 2 focused on those issues. 
 
 
Figure 1.1 Chemical structure of ginsenoside Rb1. Adapted from (Cho et al., 2004) 
 
1.2.7.2 Teasaponin 
Tea has been widely used as a healthy drink worldwide from ancient times. The earliest 
use of tea for medicinal purposes occurred in China, in roughly 2700 BC during the time 
of Emperor Shen Nung (Weisburger, 1997). During that time, it was believed to have 
health promoting properties, and was frequently used as a fluid supply for patients with 
infectious diseases. Evidence from clinical and animal studies show that tea has anti-
obesity effects (Beresniak et al., 2012a; Wolfram et al., 2006), prevent abnormal glucose 
and lipid metabolism (Beresniak et al., 2012a; Park et al., 2011), anti-inflammation 
(Henning, 2012; Park et al., 2012) and improves cognitive function (Kuriyama et al., 
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2006; Ng et al., 2008). Treatment with 1 % tea extract in diet for 6 weeks decreased body 
weight, adipose mass, hepatic TNF-α protein and adipose TNF-α mRNA, and attenuated 
hepatic steatosis in genetically obese (ob/ob) mice (Park et al., 2011). Supplementation of 
HFD with tea extract significantly reduced HFD induced p-IκBα and NF-κB activity in 
liver and adipose tissue (Park et al., 2012). Increased consumption of green tea was 
associated with a lower prevalence of cognitive impairment in a cross-sectional study in 
1003 Japanese (Kuriyama et al., 2006), and longitudinal analysis of data from 1438 
Chinese subjects (Ng et al., 2008). Phenolics and saponin are the two major active 
components extracted from tea. Phenolics in tea have been widely investigated in 
previous studies, while teasaponin has received little attention. Teasaponins, an important 
bioactive ingredient naturally extracted from varies of teas, can reduce the elevation of 
the rat plasma triacylglycerol level caused by an oral administration of a lipid emulsion 
(Han et al., 2005). Study showed that oral 0.5% teasaponin with HFD for 11 weeks 
significantly decreased body weight, parametrial adipose tissue weight and reduced the 
diameters of adipocyte (Han et al., 2001). Chemically teasaponin belongs to the 
oleanane-type pentacyclic triterpene saponins, whose amphiphilic nature enables them to 
intercalate into the cell membrane and interact with cell membrane molecules to regulate 
downstream signaling cascades (Abid et al., 2012; Attele et al., 1999a). Recently 
teasaponin (10mg/kg ip injection) showed significant anti-inflammatory properties, by 
inhibiting paw oedema induced by carrangeenan in rats (Sur et al., 2001). In the current 
study, we investigated whether teasaponin could improve central inflammation and leptin 
sensitivity in the hypothalamus and prefrontal cortex of obese mice. We further 
investigated the effect of teasaponin on neurite outgrowth in cultured primary prefrontal 
cortical neurons in response to leptin and the saturated fatty acid, palmitic acid. 
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1.3 Aims and Hypotheses 
1.3.1 Aims 
1.3.1.1 General Aim 
To evaluate the effects of triterpene saponins (Ginsenoside Rb1 or Teasaponin) on high-
fat diet-induced obesity, obesity-associated inflammation, hypothalamic leptin signaling, 
central leptin sensitivity, and cortical leptin signaling, as well as leptin-induced of BDNF 
expression and neurogenesis in the prefrontal cortex during obesity via an in vivo and an 
in vitro model.  
 
1.3.1.2 Specific Aims 
The specific aims of this research were to: 
1. Investigate the effect of ginsenoside Rb1 on high-fat diet-induced obesity, glucose 
intolerance, obesity-associated inflammation, central leptin resistance and central 
leptin signaling in the high-fat diet-induced obese mouse model. 
2. Examine the effects of ginsenosdie Rb1 on central leptin effects on BDNF expression 
and synaptogenesis in the prefrontal cortex during obesity via an in vivo and an in 
vitro model. 
3. Evaluate the effect of teasaponin on obesity, obesity-associated central inflammation 
and leptin sensitivity in the hypothalamus and prefrontal cortex of obese mice, and on 
leptin effects on BDNF and neurite outgrowth in cultured primary prefrontal cortical 
neurons in response to leptin and the saturated fatty acid, palmitic acid. 
 
1.3.2 Hypotheses 
1. Ginsenoside Rb1 will ameliorate high-fat diet-induced obesity, obesity-associated 
inflammation, glucose intolerance, and restore central leptin sensitivity, as well as central 
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leptin signaling in the high-fat diet-induced obesity. 
2. Ginsenoside Rb1 will improve central leptin effects on BDNF expression and 
synaptogenesis in the prefrontal cortex during obesity in in vivo and in vitro. 
3. Teasaponin will ameliorate obesity, central inflammation; improve memory and leptin 
sensitivity in the hypothalamus and prefrontal cortex of obese mice; and to improve 
leptin effects on BDNF and neurite outgrowth in the palmitic acid pre-treated cortical 
neurons. 
 
1.3.3 Significance 
Obesity has been reached epidemic proportions and is an important risk factor for the 
development of type 2 diabetes, cardiovascular disease and cancer. It is generally 
accepted that a large component of obesity-associated pathophysiology may stem from a 
low-grade pro-inflammation that occurs during obesity. The pro-inflammatory response 
includes elevated pro-inflammatory cytokines and activation of NFκB signaling pathway. 
The activation of pro-inflammatory cytokines and NFκB signaling pathway induce 
insulin and leptin resistance in the peripheral tissue and the central nervous system. 
Obesity-associated inflammation in white adipose tissue and the liver leads glucose 
intolerance, insulin resistance and metabolic dysfunction. Over-nutrition and obesity also 
leads to hypothalamic inflammation. Hypothalamic inflammation results in the central 
leptin resistance, hepatic insulin resistance, a reduction in thermogenesis, and 
cardiovascular disorders. Furthermore, obesity impairs prefrontal cortex, which is a major 
regulatory center for cognitive function. Obesity impairs leptin-induced regulation of 
BDNF expression, neurite outgrowth and synaptogenesis, which has been considered to 
be associated with the incidence of neuronal degenerative diseases, cognitive decline, and 
depression. Therefore, strategies to attenuate the obesity-associated peripheral and 
hypothalamic inflammation, central leptin resistance and impairment of cortical leptin-
BDNF, neurite outgrowth and synaptogenesis may help to prevent the risk of 
development obesity-associated metabolic disorder and neurodegeneration. 
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Studies showed that some triterpene saponins are naturally derived inhibitors of NFκB 
signaling and have anti-inflammatory potential. Ginsenoside Rb1, one of the triterpene 
saponin, has been reported to have anti-inflammation effect, anti-obesity effect and 
neuroprotective effect.  Reports also indicated, tea and tea extract (including teasaponin) 
has anti-inflammatory effect. However, it is unknown whether Rb1 can improve obesity-
associated inflammation and leptin resistance, and also unknown the effects of Rb1 on 
leptin-BDNF, neurite outgrowth. It is also unclear the effects of teasaponin on obesity-
associated hypothalamic inflammation, obesity-associated leptin resistance, leptin-
mediated BDNF expression and leptin-mediated neurite outgrowth, as well as obesity-
associated recognition impairment. This research will explore chronic treatment effects of 
Rb1 on obesity-associated inflammation and central leptin resistance, cortical leptin 
sensitivity and synaptogenesis, as well as effects of teasaponin on obesity-associated 
hypothalamic inflammation, obesity-linked recognition impairment, and hypothalamic 
and cortical leptin sensitivity. This research will provide new potential anti-obesity 
therapeutic agents that will modulate obesity-associated inflammation, central leptin 
sensitivity and prevent obesity-associated neurodegeneration.   
 
1.4 General Methods and Materials 
1.4.1 Ethics statement 
All procedures of animal studies included in this study were approved by the Animal 
Ethics Committee of the University of Wollongong, NSW, Australia (Application 
Approval#: AE10/08), and complied with the Australian Code of Practice for the Care 
and Use of Animals for Scientific Purposes, which is in accordance with the International 
Guiding Principles for Biomedical Research Involving Animals. All efforts have been 
made to minimize animal numbers, animal stress and prevent suffering.  
 
1.4.2 Animals care and Drug Treatments 
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C57Bl/6 male mice were obtained from the Animal Resources Centre (Perth, Western 
Australia) and housed in environmentally controlled conditions (temperature 22 °C, 12 
hour light/dark cycle). All animals were fed a lab chow (LC) diet (5% fat, Vella Stock 
Feeds, Doonside, NSW, Australia) ad libitum to acclimatize for one week. Throughout 
the study, LC was served as the low fat control diet and was provided ad libitum except 
where noted.   
 
1.4.2.1 Acute Ginsenoside Rb1 treatment for central leptin sensitivity test 
In study 1 (chapter 2), after acclimatization, mice were fed a HFD for 8 weeks to generate 
the moderate obesity mice (The HFD contained 40% of energy as fat, SF11-095, 
Specialty Feeds, Western Australia). Then an intracerebroventricular cannula was 
implanted (detailed in section 1.3.4). After 5 days of recovery, the obese mice were then 
acute treated with Rb1 by intraperitoneal injected with Rb1 for two consecutive days. 
Central leptin sensitivity was then carried out on the mice (detailed in section 1.4.4). The 
dosage of Rb1 was 14 mg/kg, based on a Rb1 dose (10mg/kg) described previously in 
rats (Xiong et al., 2010), and using a body surface area ratio of 0.14 from rat to mouse 
(Paget and Barnes, 1964). Rb1 purified by high-performance liquid chromatography 
(HPLC) to ≥98% was purchased from Jilin University in China. 
 
1.4.2.2 Chronic Ginsenoside Rb1 treatment  
In study 1 (chapter 2) and study 2 (chapter 3), after acclimatization, mice were then fed a 
HFD for 16 weeks to induce the late stage of obesity. After 16 weeks of HFD, obese mice 
were randomized into two groups (n=16 per group) and chronic treated with either daily 
intraperitoneal (ip) injections of Rb1 (14 mg/kg) or vehicle (saline) for 21 days. This 
study also included a parallel control group of age-matched mice fed a LC diet. During 
Rb1 treatment the animal’s food intake and body weight were recorded daily. On day 18 
of Rb1 treatment, an intraperitoneal glucose tolerance test was performed (detailed in 
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section 1.4.3). On day 21 of Rb1 treatment, an intracerebroventricular cannula was 
implanted and central leptin sensitivity test was performed (detailed in section 1.4.4). 
Figure 1.2 was the flow chart of triterpene saponin chronic treatment on experimental 
obese mice. 
This part of chronic Rb1 treatment was both included in chapter 2 and chapter 3. 
 
Figure 1.2 Flow chart of triterpene saponin chronic treatment on experimental obese mice. 
Wks: weeks; D: day; GTT: glucose tolerance test; BW: body weight; FI: food intake; h: hour (s); 
icv: intracerebroventricular. 
 
1.4.2.3 Chronic Teasaponin treatment  
In study 3 (chapter 4), mice were placed on the HFD for 16 weeks. The animals were 
then randomized into two groups, and administered either teasaponin (10 mg/kg) or 
vehicle (saline) i.p. injections daily for 21 days. Age-matched, LC diet control mice were 
maintained on the lab chow diet. Body weight and food intake were measured daily. 
Teasaponin (96%, C57H90O26, MW=1200) was purchased from the Aladdin Chemistry 
Co. Ltd, China. On day 18 of TS treatment, an intraperitoneal glucose tolerance test was 
performed (detailed in section 1.4.3). On day 21 of TS1 treatment, an 
intracerebroventricular cannula was implanted and central leptin sensitivity test was 
performed (detailed in section 1.4.4). Figure 1.2 showed the flow chart experiment. 
This part of chronic teasaponin treatment was included in chapter 4. 
 
1.4.3 Intraperitoneal glucose tolerance test (IPGTT) 
On day 18 of Rb1 (or Teasaponin) treatment, the mice were injected intraperitoneally 
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with glucose at a dose of 0.5 g/kg after an overnight fasting. Blood samples were taken 
from the tail vein, and blood glucose concentration determined using a glucometer 
(Freestyle; Abbott Diabetes Care, Alameda, CA) at 0 (fasting), 30, 60 and 120 minutes 
after glucose injection. 
 
1.4.4 Central leptin sensitivity 
Mice were anesthetized by isoflurane inhalation and placed in a stereotactic device. An 
intracerebroventricular (icv) cannula was implanted into the right lateral brain ventricle 
(0.25 mm posterior and 1.0 mm lateral relative to Bregma and 2.5 mm below the surface 
of the skull) (Paxinos and Franklin, 2002). Five days after implantation the mice were 
fasted for 6 hours, and either leptin (0.1 µg/3 µl) or saline (3 µl) was injected into the 
lateral ventricle through the cannula. Food intake was measured for 1, 4, and 24 hours, 
and body weight was measured 24 hours after the leptin or vehicle injection. 
The accuracy of the cannula placement was histologically confirmed by the methylene 
blue which was icv injected into the pre-experimental test animal before decapitated. The 
cannula track of each animal was confirmed when sliced the brain. Figure 1.2 showed the 
confirmation of correct placement of cannula. 
 
 
Yizhen Wu                                                                                                                                                 22 
 
Figure 1.3 A pre-experimental histologically confirmation of the correct cannula placement at the 
lateral ventricle and the correct location of injection were carried out using a Methylene Blue 
injection (A). The accuracy of the cannula placement of the experimental animals was comfirmed 
by examing the cannula track in the brain section of each animal. Sections were compared with the 
corresponding section from the mice brain atlas (B). 
 
1.4.5 Blood and Tissue collection 
Following a further four day interval after examining central leptin sensitivity, mice were 
fasted for 6 hours, administered an icv injection of either leptin (0.1 µg/3 µl) or saline (3 
µl) and then euthanized 1 hour later for tissue collection. Blood, white adipose tissue, 
liver and brain tissue were collected. The plasma was collected after centrifugation at 
3000rpm for 15 minutes. Plasma and other tissues were stored at -80 °C for further 
analyses.  
Using a standard mouse brain atlas (Paxinos and Franklin, 2002), 500 µm frozen brain 
sections were cut from Bregma -1.22 mm to -2.72 mm (for mediobasal hypothalamus), 
Bregma 2.8-1.98 mm (for prefrontal cortex) using a cryostat at a temperature of -18 °C. 
The mediobasal hypothalamus were dissected and then collected using a Stoelting Brain 
Punch (#57401, 0.5 mm diameter, Wood Dale, Stoelting Co, USA) in an overlapping 
pattern over the 3rd ventricle (White et al., 2009). The prefrontal cortex was also 
dissected and collected by the stoelting brain punch. 
1.4.6 Determination of plasma leptin, insulin, peptide YY (PYY) and 
adiponectin 
Plasma leptin, insulin and PYY were measured using the mouse metabolic magnetic bead 
panel kit (Merck Millipore, MA), and adiponectin was assayed with the mouse single 
plex adiponectin kit (Merck Millipore). 
 
1.4.7 Histological analysis and morphometry 
Epididymal fat was fixed in 10% buffered formaldehyde and then embedded in paraffin. 
Tissue sections (5 μm) were cut and mounted onto polysine slides. The sections were 
stained with hematoxylin and eosin and photographed at 100× magnification. Using the 
Yizhen Wu                                                                                                                                                 23 
 
image analysis software Image J 1.46r (http://rsbweb.nih.gov/ij/download.html), two 
fields per section and six sections per fat mass were analyzed to quantify the area and 
number of adipocytes. 
 
1.4.8 Western blot analysis 
As described in our previous study (du Bois et al., 2012), tissue protein from liver (study 
1, chapter 2), epididymal fat (study 1, chapter 2), mediobasal hypothalamus (study 1, 
chapter 2) and prefrontal cortex (study 2, chapter 3; and study 3, chapter 4) was extracted 
using NP-40 Lysis Buffer. The following antibodies were used: TNF-α (sc-8301), IL-1β 
(sc-7884), IL-6 (sc-7920), pJAK2 (sc-21870), BDNF (sc-20981), TrkB (sc-), and pAkt 
(sc-) from Santa Cruz Biotechnology (Dallas, TX); pTrkB 95  from Sigma-Aldrich (St. 
Louis, MO, USA); and p-IκBα (#2859), p-IKK (#2697), p-STAT3 (#9145), SOCS3 
(#2932), and p-FOXO1 (#9461), pGSK3β (#) from Cell Signaling Technology (Beverly, 
MA). Bands corresponding to the proteins of interest were analyzed using the automatic 
imaging analysis system Quantity One (Bio-Rad Laboratories, Hercules, CA). All 
quantitative analyses were normalized to β-actin as described in our previous study (du 
Bois et al., 2012).  
1.4.9 Novel object recognition test 
In animal study 3 (chapter 4), novel object recognition test was performed. This test is 
based on the innate tendency of rodents to differentially explore novel objects over 
familiar ones as previously described (Arqué et al., 2008), with minor modifications. In 
brief, the experimental procedure consisted of habituation, training, and retention 
sessions. On day 1, for habituation, mice were placed into an open-field box (55 × 55 cm 
× 35 cm high) for 10 min with a 40 W light bulb in a sound proof room. On day 2, during 
the training session, two identical objects (A) were placed at opposing corners of the box, 
5 cm from the adjacent wall. Each mouse was then placed in the middle of the open-field 
box and left to explore the objects for 10 min. Ninety minutes later, in the retention 
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session, one familiar object (A) was replaced with one novel object (B). Each mouse was 
placed in the middle of the open-field box, and left to explore for another 10min. The 
exploration time for the familiar and the new objects was recorded. Memory was 
operationally defined by the discrimination index for the novel object (DI) as the 
proportion of time animals spent investigating the novel object minus the proportion 
spent investigating the familiar one in the testing period in the retention session 
[Discrimination Index = (Novel Object Exploration Time/Total Exploration Time) – 
(Familiar Object Exploration Time/Total Exploration Time) × 100]. 
 
1.4.10 Primary prefrontal cortical neuronal cultures and treatment 
Primary prefrontal cortical neuronal cultures was applied both in study 2 (Chapter 3) and 
study 3 (Chapter 4). Mouse prefrontal cortical neuronal cultures were prepared from pups 
at postnatal day 1-2 (C57Bl/6J mice, Perth, Western Australia) as described previously 
(Hilgenberg and Smith, 2007). Dissociated cells were seeded at an approximate final 
density of 1 x 10
5
 cells/cm2 into a Poly-D-Lysine-coated 24-well plate (1.9 cm
2
/well) for 
qRT-PCR measurement. For neuronal morphology measurement, the neurons were 
cultured on Poly-D-Lysine-coated glass coverslips. In study 2 (Chapter 3), at 7 days in 
vitro, Rb1 (40 µM, refer to (Liao et al., 2002)) was used to treat the cultures 
simultaneously in the presence of palmitic acid (final concentration of 10 µM, P5585, 
Sigma-Aldrich, St Louis, MO, USA). Palmitic acid was dissolved following the method 
described previously (Ross et al., 2010). Four hours after palmitic acid and/or Rb1 pre-
exposure, leptin (100 ng/mL, refer to (Valerio et al., 2006), Cat#: 450-31, Peprotech, 
Rocky Hill, NJ, USA) or vehicle was added to the cultures for another 44 hours before 
the cells were harvested.  
In study 3 (Chapter 4), at 7 days in vitro, 20 µM or 40 µM teasaponin was used to treat 
the cultures simultaneously in the presence of palmitic acid (10 µM). Four hours after 
palmitic acid and/or TS pre-exposure, leptin (100 ng/mL, refer to (Valerio et al., 2006), 
Cat#: 450-31, Peprotech, Rocky Hill, NJ, USA) or vehicle was added to the cultures for 
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another 44 hours before the cells were harvested.  
 
1.4.11 Quantitative real-time PCR (qPCR) 
Total mediobasal hypothalamic RNA (study 1, Chapter 2), and total RNA from cultured 
cells (study 2, Chapter 3; and study 3, Chapter 4) were extracted using the Aurum total 
RNA mini kit (Bio-Rad Laboratories, Hercules, CA) and reverse-transcribed to first-
strand complementary DNA with the high-capacity cDNA reverse transcription kit (AB 
Applied Biosystems, Carlsbad, CA), according to the manufacturer’s instructions. qPCR 
was performed in a 20 µl final reaction volume using SYBR green I master in a 
Lightcycler 480 (F. Hoffmann-La Roche Ltd, Basel, Switzerland). Primers used are listed 
in the table of each chapter. Amplification was carried out with 45 cycles of 95 °C for 10 
seconds, 60 °C for 30 seconds and 72 °C for 30 seconds. The mRNA expression levels 
for hypothalamic neuropeptides (study 1, Chapter 2), MAP2, PSD95, SYN and BDNF 
(study 2, Chapter 3; and study 3, Chapter 4) were normalized to gamma actin, which 
served as the internal control. Experiments were performed in triplicate. The level of 
expression for each gene was calculated using the comparative threshold cycle value (Ct) 
method, using the formula 2–ΔΔCt as described previously (Livak and Schmittgen, 2001; 
Wilusz et al., 2008). 
 
1.4.12 Immunofluorescence 
Immunofluorescence and image analysis were applied in the study 2 (Chapter 3) and 
study 3 (Chapter 4). For immunocytochemical staining, neurons were washed three times 
in phosphate-buffered saline (PBS), and then fixed with 4% paraformaldehyde (Sigma-
Aldrich, St Louis, MO, USA) for 30 min at room temperature. After rinsing with PBS, 
the neurons were permeabilized with 0.3% Triton-X (Sigma-Aldrich) in PBS (i.e. PBST) 
for 10 min, and blocked with 5% goat serum in PBST for 1 hour at room temperature. 
Then anti-BDNF antibody, anti-microtubule-associated protein 2 (MAP2) antibody, anti-
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synaptophysin (SYN) antibody, and anti-post-synaptic density protein 95 (PSD 95) 
antibody were applied overnight at 4°C. MAP2 was visualized by goat anti-mouse 
secondary antibody conjugated with Alexa Fluor 594. BDNF, SYN, and PSD95 were 
visualised with isotype-specific donkey anti-rabbit secondary antibody conjugated with 
Alexa Fluor 488. The details of origin and concentration of antibodies were given in the 
Table S1. A fluorescence microscope (Axiovert 200, Carl Zeiss, Oberkochen, Germany) 
with an attached digital camera was used to obtain MAP2 immunofluorescence images 
for neuronal morphology analysis. A confocal microscope (Leica TCS SP5 Advanced 
System, Wetzlar, Germany) equipped with a digital camera was used to obtain images for 
immunoreactivity analysis of BDNF, PSD95, and SYN.  
 
1.4.13 Neurite length and branching analysis 
Neurite length and branching analysis were applied in the study 2 (Chapter 3) and study 3 
(Chapter 4).  The analysis was performed by the NeuriteQuant program (Dehmelt et al., 
2011), which is an open source toolkit ―NeuriteQuant V1.23‖ (http://www.ccb.tu-
dortmund.de/groups/CB/bastiaens/dehmelt/Neurite Quant/) that to be installed as a plugin 
for image J 1.40g (http://rsbweb.nih.gov/ij/download.html). The quantification of 
neuronal morphology included: average neurite length, neurite length per cell, neurite 
number per cell, branches per neurite, and branches per cell. Experiments were 
independently performed three times, with each time repeated in triplicate (n=9). The 
image analysis was based on these nine repeats.  
 
1.4.14 Immunoreactivity analysis for BDNF, PSD95, and SYN 
In study 2 (Chapter 3), software Image J 1.40g was used to quantify the 
immunoreactivity of BDNF, PSD95, and SYN. Images were converted into a 16-bit scale 
for analysis. The mean intensity of the fluorescence of these biomarkers in the cell body 
was measured. Approximately 1-2 areas (around 10x10 μm
2 
per area) of the cell body per 
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neuron were analyzed and 7-8 neurons per image were randomly selected. A range of 6-7 
images per group from three independent experiments were analyzed. For PSD95 and 
SYN, dendrite immunoreactivity was also analyzed. In each dendrite, 2-4 areas (around 
10x10 μm
2 
per area) were measured, and 2-4 dendrites per neuron were analyzed. 
 
1.4.15 Statistical analysis 
Data were analyzed using the SPSS 19 statistical package (SPSS, Chicago, IL). The two-
tailed student’s t-test was used to compare food intake, adipose tissue histology and 
weight, inflammatory markers in epididymal adipose tissue and liver, and hypothalamic 
neuropeptides in study 1 (Chapter 2). One-way analysis of variance (ANOVA) was 
followed by the post hoc Tukey–Kramer honestly significant difference (HSD) test was 
used to analyze final body weight gain, body weight, energy intake, epididymal fat, 
visceral fat, liver weight, glucose tolerance test, novel recognition test, plasma cytokines, 
central inflammatory markers, central leptin sensitivity, as well as biomarkers of the in 
vitro study and neuronal morphology data (study 1-3). A p<0.05 was regarded as 
statistically significant, and p<0.10 were considered a trend. Values are expressed as 
mean  SEM. 
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CHAPTER TWO 
Central Inflammation and Leptin Resistance Are Attenuated by 
Ginsenoside Rb1 Treatment in Obese Mice Fed a High-Fat Diet 
 
Reprinted from PLOS ONE, Open-access 
Available at:  http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0092618 
 
Yizhen WU                                                                                                                                                   29 
 
Statement from co-authors 
 
This is to attest that the PhD candidate, Yizhen Wu, contributed significantly to the 
investigation 
Wu, Y., Y. Yu, A. Szabo, M. Han, and X.-F. Huang. 2014. Central Inflammation and Leptin 
Resistance Are Attenuated by Ginsenoside Rb1 Treatment in Obese Mice Fed a High-Fat Diet. 
PLoS ONE. 9:e92618. 
Yizhen Wu designed and performed the experimental work, analysed the data, interpreted data, 
and wrote the manuscript. Y. Yu and X.-F. Huang are supervisors, who have provided 
comments on experimental design, data analysis, and results interpretation. A. Szabo, and M. 
Han contributed to the discussion. 
Yizhen WU:  
 
Yinghua Yu: 
   
Alexander Szabo: 
 
Mei Han: 
 
Xu-Feng Huang:   
  
Yizhen WU                                                                                                                                                   30 
 
Yizhen WU                                                                                                                                                   31 
 
Yizhen WU                                                                                                                                                   32 
 
Yizhen WU                                                                                                                                                   33 
 
Yizhen WU                                                                                                                                                   34 
 
Yizhen WU                                                                                                                                                   35 
 
Yizhen WU                                                                                                                                                   36 
 
Yizhen WU                                                                                                                                                   37 
 
Yizhen WU                                                                                                                                                   38 
 
Yizhen WU                                                                                                                                                   39 
 
 
  
Yizhen WU                                                                                                                                                   40 
 
Table S1 The primers used in qPCR for neuropeptide mRNA measurement  
GENE Forward primer Reverse primer NCBI reference 
NPY ATACTACTCCGC
TCTGCGAC 
GTGTCTCAGGGCTG
GATCT 
NM_023456.2 
AgRP AGTTGTGTTCTG
CTGTTGGC 
CTGATGCCCTTCAG
TGGAG 
NM_007427.2 
POMC CCATAGATGTGT
GGAGCTGG 
CCAGCGAGAGGTC
GAGTT 
NM_008895.3 
γ-actin GCTAACAGAGA
GAAGATGACG 
CAGATGCATACAAG
GACAGC 
NM_009609.2 
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Table S2 Effects of acute Rb1 administration (14 mg/kg, ip, two days) on 
body weight and food intake in obese mice after a high-fat diet feeding for 8 
weeks 
 
HF 
 
HF + Rb1 
BW before Rb1 treatment (g) 29.84 ± 0.49 
 
29.59 ± 0.47 
BW after Rb1  treatment (g) 30.12 ± 0.47 
 
29.89 ± 0.43 
FI of 24 hours after Rb1 treatment (g) 3.39 ± 0.16 
 
3.44 ± 0.10 
HF: high-fat diet-induced obese mice; Rb1: ginsenoside Rb1 treatment; BW: 
body weight; FI: food intake. Data are presented as mean ± SEM.  
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CHAPTER THREE 
Ginsenoside Rb1 Improves Leptin Sensitivity in the Prefrontal Cortex in 
Obese Mice 
 
Reprinted from CNS Neuroscience & Therapeutics, Copyright (2018), with permission 
from  
Available at:  http://onlinelibrary.wiley.com/doi/10.1111/cns.12776/abstract 
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SUPPLEMENTARY DATA 
Table S1. The antibodies used in this study 
Peptide/protein 
target 
Name of Antibody Manufacturer, catalog # Species raised in 
monoclonal or polyclonal 
Dilution 
used 
 
Experiment 
BDNF BDNF (H-117) Santa Cruz Biotechnology, sc-20981 Rabbit, Polyclonal 1:400  Western blot 
p-JAK2 p-JAK2 (Tyr 1007/Tyr 
1008) 
Santa Cruz Biotechnology, sc-21870 Goat, Polyclonal 1:500 Western blot 
p-STAT3 Phospho-Stat3 (Tyr705) 
(D3A7) XP
®
 Rabbit 
mAb 
Cell Signaling Technology, #9145 Rabbit, Monoclonal 1:2000 Western blot 
BDNF BDNF (H-117) Santa Cruz Biotechnology, sc-20981 Rabbit, Polyclonal 1:100 Immunofluorescence 
MAP2 Monoclonal Anti-MAP2 
antibody  
Sigma-Aldrich, #M4403 Mouse, Monoclonal  1:500 Immunofluorescence 
SYN Anti-Synaptophysin 
antibody  
Sigma-Aldrich, SAB4502906 Rabbit, Polyclonal 1:100 Immunofluorescence 
PSD95 Anti-PSD-95 antibody  Life Technologies, #51-6900 Rabbit, Polyclonal 1:500 Immunofluorescence 
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Table S2. Primers used in qPCR for mRNA measurement of synaptogenesis markers 
Gene Forward primer Reverse primer NCBI reference 
BDNF GGGTCACAGCGGCAGATAAA GCCTTTGGATACCGGGACTT NM_001285416.1 
MAP2 ATGAAGGAAAGGCACCACAC AATAGGTGCCCTGTGACCTG NM_001039934.1 
SYN GAACAAGTACCGAGAGAACAACAA GGTCAGTGGCCATCTTCACA NM_009305.2 
PSD95 GGTGACGACCCATCCATCTTTATC CGGACATCCACTTCATTGACAAAC NM_007864.3 
γ-actin GCTAACAGAGAGAAGATGACG CAGATGCATACAAGGACAGC NM_009609.2 
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Table S3. Central leptin sensitivity and plasma level of leptin in experimental groups in response to icv leptin administration 
    LC   obese   obese + Rb1 
    Saline Leptin   Saline Leptin   Saline Leptin 
Central leptin sensitivity               
EI_1 hr. icv (Kcal) 2.3 ± 0.3 1.6 ± 0.4 
 
1.0 ± 0.1 0.9 ± 0.1 
 
0.5 ± 0.1
b
 0.4 ± 0.1
c
 
EI_4 hrs. icv (Kcal) 5.2 ± 0.6 3.1 ± 0.4a 
 
5.1 ± 0.6 4.9 ± 0.6 
 
3.2 ± 0.4b 1.6 ± 0.2cd 
          
Leptin  (ng/mL) 0.6 ± 0.1 0.7 ± 0.1   16.9 ± 2.1
a
 17.3 ± 1.8   8.9 ± 1.1
ab
 8.3 ± 1.4c 
Central leptin sensitivity: Energy intake (EI) for 1, and 4 hours after icv leptin administration. LC: Lab-chow diet fed mice; obese: 
obese mice induced by a high-fat diet; obese + Rb1: obese mice treated with Rb1 for 3 weeks. 
a
p<0.05 vs. LC/saline group; 
b
p<0.05 vs. obese/saline group; 
c
p<0.05 vs. obese/leptin group; 
d
p<0.05 vs. (obese + Rb1)/saline group. 
Data are presented as mean ± SEM, n=6-8. 
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Table S4. The levels of PSD95 and SYN mRNA expression in cultured prefrontal cortical neurons 
  Saline   Leptin 
  Control PA  PA + Rb1 
 
Control PA  PA + Rb1 
PSD  100.0 ± 9.7 105.6 ± 2.8 119.0 ± 3.3 
 
139.1 ± 5.6a 103.6 ± 1.8b 130.7 ± 8.4
c
 
SYN 100.0 ± 7.4 92.5 ± 6.8 107.3 ± 9.2   142.3 ± 9.7
a
 93.6 ± 8.7
b
 110.8 ± 6.5 
PSD95: post-synaptic density protein 95; SYN: synaptophysin. PA: palmitic acid; Rb1: ginsenoside Rb1. Cultured primary 
cortical neurons were treated on the 7th day of in vitro, with 10 μM PA or (10 μM PA +  40 μM Rb1) for 4 hours, then 
supplemented with 100ng/mL leptin or vehicle for 44 hours more. After 48 hours' treatment, neurons were collected to 
examine the mRNA expression levels of PSD95 and SYN. 
a
p<0.05 vs. respective saline group; 
b
p<0.05 vs. control/leptin; 
c
p<0.05 vs. PA/leptin. Data were presented as Mean ± SEM, n=5-7. 
 
 
 
Yizhen Wu                                                                                                                                                58 
 
CHAPTER FOUR 
Teasaponin improves hypothalamic and cortical leptin sensitivity in diet-
induced obese male mice 
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Teasaponin improves hypothalamic and cortical leptin sensitivity in 
diet-induced obese male mice 
 
 
Abstract: 
Hypothalamic inflammation is involved in the pathogenesis of obesity and type 2 diabetes. 
Obesity impairs cognition, and the leptin-induced increase of brain-derived neurotrophic factor 
(BDNF) and neurogenesis. Tea consumption improves inflammation, cognition and increases 
brain activation in the prefrontal cortex. This study examined whether teasaponin, an active 
ingredient in tea, could improve central inflammation and leptin sensitivity in the 
hypothalamus and prefrontal cortex of obese mice. Teasaponin (10mg/kg, intraperitoneal) for 
21 days significantly decreased the food intake and body weight of high-fat (HF) diet-induced 
obese mice. In the hypothalamus teasaponin decreased both pro-inflammatory cytokines and 
inflammatory signaling in the mediobasal hypothalamus. Teasaponin treatment also enhanced 
the anorexigenic effect of central leptin administration, restored leptin p-STAT3 signaling in 
the hypothalamus. Furthermore, teasaponin improved downstream leptin signaling (JAK2, and 
STAT3), and leptin’s effect on BDNF, in the prefrontal cortex of HF fed mice. Prefrontal 
cortical neurons were cultured with teasaponin and palmitic acid (the most abundant dietary 
saturated fatty acid) to examine their effects on BDNF and neurite outgrowth in response to 
leptin. Palmitic acid decreased leptin’s effect on BDNF and neurite outgrowth in cultured 
cortical neurons, which were reversed by teasaponin. Therefore, teasaponin supplementation 
may be used to prevent obesity-associated neurodegeneration and improve cognitive function.  
  
Keywords: Teasaponin, anti-inflammation, leptin sensitivity, diet-induced obesity 
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4.1 Introduction 
Obesity has reached epidemic proportions and is an important risk factor for the development 
of type 2 diabetes, cardiovascular disease, and some forms of cancer. There is compelling 
evidence that a large component of obesity-associated pathophysiology may stem from the 
low-grade inflammation that occurs during obesity. This includes increased production of pro-
inflammatory cytokines such as tumour necrosis factor alpha (TNF-α), interleukin 1 beta (IL-
1β) and interleukin 6 (IL-6), and activation of the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) inflammatory signaling pathway in adipose tissue, liver and the 
hypothalamus of the brain (Osborn and Olefsky, 2012; Thaler et al., 2012).  
Over nutrition induces inflammatory responses in peripheral metabolic tissues, including the 
infiltration of pro-inflammatory cytokine secreting macrophages into the adipose tissue of 
obese mice and humans (Osborn and Olefsky, 2012; Weisberg et al., 2003; Xu et al., 2003). 
Recent research has identified a similar type of low-grade inflammation in the hypothalamus of 
rodents (Thaler et al., 2012), where TNF-α, IL-6 and IκB kinase (IKK) mRNA expression are 
increased within a week of starting a HFD. IKK along with inhibitor kappa B alpha (IκBα) are 
components of the NF-κB signaling pathway, and commonly used to investigate inflammatory 
signaling events. Hypothalamic inflammation results in central leptin resistance, hepatic insulin 
resistance, a reduction in thermogenesis and cardiovascular disorders (Cai and Liu, 2012). 
Therefore, blocking the peripheral and central inflammation induced by HFD has the potential 
to treat obesity and metabolic syndrome. This could be achieved using novel therapies 
incorporating effective natural agents, particularly agents with the dual properties of preventing 
inflammation and controlling body weight.  
Recent epidemiological studies have demonstrated that obesity increases the incidence of 
cognitive decline in neurodegenerative diseases, such as vascular dementia (Hassing et al., 
2002; Singh-Manoux et al., 2012). Empirical evidence has linked high-fat diet (HF)-induced 
obesity with impairments in learning and memory, including a decline in recognition memory 
(Boitard et al., 2014b; Camer et al., 2015; Valladolid-Acebes et al., 2011). For example, HF for 
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8 weeks impairs spatial learning in the eight-arm radial maze test, prior to metabolic alterations 
linked to obesity developing and without significant changes in plasma glucose and insulin 
levels (Valladolid-Acebes et al., 2011). HF treatment of juvenile rodents impairs long-term 
spatial reference memory in the Morris water maze, without affecting acquisition or short-term 
memory (Boitard et al., 2014b). Furthermore, in our previous study, recognition memory was 
impaired in chronic HF fed mice as assessed by performing a novel object recognition test 
(Camer et al., 2015). The prefrontal cortex plays an important role in higher cognitive function 
(Cole et al., 2012a). Abnormal structure and dysfunction in the prefrontal cortex is associated 
with cognitive decline and the pathogenesis of mood disorders (Fumagalli et al., 2003; Kanoski 
et al., 2007b; Weickert et al., 2003). Furthermore, positron emission tomography has shown 
that obese women have reduced activation in the prefrontal cortex in response to a meal than 
lean women (Le et al., 2007). In preclinical animal studies, a high-fat diet reduces synaptic 
plasticity in the prefrontal cortex (Val-Laillet et al., 2011b), which leads to learning and 
memory impairments (Laroche et al., 2000a). Moreover, obese patients are leptin resistant and 
have significantly higher levels of plasma leptin, which correlates with body fat mass 
(Heymsfield et al., 1999). Our previous study showed that in rodents a high saturated fat diet 
induces body weight gain followed by the development of obesity, which is accompanied by 
peripheral and then brain leptin resistance (Lin et al., 2000b). Despite this, therapeutic 
interventions targeting HF-induced cognitive impairment and central leptin resistance are 
lacking.  
The adipocyte-secreted hormone leptin has important effects on synaptogenesis and dendritic 
morphology in the brain, which regulate energy homeostasis and facilitate learning and 
memory (Bariohay et al., 2005b; Komori et al., 2006; Yamada et al., 2011). For example, in 
vitro, leptin increases neurite outgrowth marker and synaptogenesis markers in mouse H19-7 
HN neural cell lines, as well as stimulating hippocampal neurogenesis by increasing cell 
proliferation and differentiation (Moon et al., 2013). Leptin replacement at physiological doses 
for two years substantially increased the rate of development in most neurocognitive domains 
in dividual with leptin gene mutation (Paz-Filho et al., 2008). Brain-derived neurotrophic factor 
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(BDNF) plays an important role in synaptic plasticity and neurogenesis (Arancio and Chao, 
2007; Noble et al., 2011), cognitive function (Grassi-Oliveira et al., 2008) and energy 
metabolism (Yu et al., 2009) through the activation of its receptor, tropomyosin-related kinase 
B (TrkB). BDNF is broadly expressed in the developing and adult mammalian brain, 
particularly in the cerebral cortex, hippocampus, hypothalamus and brainstem (Noble et al., 
2011). Plasma BDNF levels are positively correlated to memory performance in female 
patients with major depressive disorder (Grassi-Oliveira et al., 2008). Leptin administration 
significantly increases hippocampal BDNF in control but not HF-induced obese mice 
suggesting decreased central leptin sensitivity in obese mice (Yamada et al., 2011). Altogether, 
this evidence suggests that leptin activation of BDNF in the central nervous system may be 
involved in cognition, while brain leptin resistance could contribute to obesity related cognitive 
decline. 
From ancient times tea has been widely used as a healthy drink worldwide. Recent evidence 
has emerged that tea can prevent obesity and abnormal glucose and lipid metabolism 
(Beresniak et al., 2012b; Wolfram et al., 2006). The earliest use of tea for medicinal purposes 
occurred in China, in roughly 2700 BC during the time of Emperor Shen Nung (Weisburger, 
1997). During that time, it was believed to have health promoting properties, and was 
frequently used as a fluid supply for patients with infectious diseases. Recently, the effect of 
tea on inflammation has received increasing attention. Six cups of green tea daily for three to 
eight weeks significantly reduced NF-κB signalling in men with prostate cancer prior to 
undergoing prostatectomy, compared to the control group (Henning, 2012). Treatment of 
genetically obese (ob/ob) mice with 1 % tea extract in diet for 6 weeks decreased hepatic TNF-
α protein, adipose TNF-α mRNA, and attenuated hepatic steatosis (Park et al., 2011). Increased 
consumption of green tea was associated with a lower prevalence of cognitive impairment in a 
cross-sectional study in 1003 Japanese (Kuriyama et al., 2006), and longitudinal analysis of 
data from 1438 Chinese subjects (Ng et al., 2008). Phenolics and saponin are the two major 
active components of tea extract. Phenolics in tea have been widely investigated in previous 
studies, while teasaponin (TS), an important bioactive ingredient of tea extract, has received 
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little attention. Teasaponin chemically, belongs to the oleanane-type pentacyclic triterpene 
saponins, which are naturally derived inhibitors of NF-kB signaling and have anti-
inflammatory potential (Salminen et al., 2008a). Recently teasaponin (10mg/kg ip injection) 
showed significant anti-inflammatory properties, by inhibiting paw oedema induced by 
carrangeenan in rats (Sur et al., 2001). In the current study, we expanded these findings to 
investigate the effect of teasaponin on recognition memory and leptin signaling in the 
hypothalamus and prefrontal cortex of HF fed mice. We further investigated the effect of 
teasaponin in cultured primary prefrontal cortical neurons in response to leptin and the 
saturated fatty acid, palmitic acid. 
 
4.2 Materials and Methods: 
4.2.1 Animals 
C57Bl/6J male mice (10 weeks old, body weight: 19.6 ± 1.4 g) were obtained from the Animal 
Resources Centre (Perth, Western Australia), and housed in environmentally controlled 
conditions (temperature 22 °C, 12 hour light/dark cycle). Lab chow (LC) served as the low-fat 
control diet (5% fat, Vella Stock Feeds, Doonside, NSW, Australia) and was provided ad 
libitum except where noted. Mice were acclimatised for one week prior to experimentation. All 
procedures were approved by the Animal Ethics Committee, University of Wollongong, NSW, 
Australia, and complied with the Australian Code of Practice for the Care and Use of Animals 
for Scientific Purposes. 
 
4.2.2 Intraperitoneal (ip) teasaponin treatment 
Mice were placed on the HF (containing 60% fat by calories, Specialty Feeds, Western 
Australia) for 16 weeks. The animals were then randomised into two groups, and administered 
either teasaponin (10 mg/kg) or vehicle (saline) i.p. injections daily for 21 days. Age-matched, 
LC diet control mice were maintained on the lab chow diet. Body weight and food intake were 
measured daily. Teasaponin (96%, C57H90O26, MW=1200) was purchased from the Aladdin 
Chemistry Co. Ltd, China. 
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4.2.3 Intraperitoneal glucose tolerance test (IPGTT) 
 On day 18 of the teasaponin treatment, the mice were fasted overnight and given an ip 
injection of glucose (0.5g/kg) as reported previously (Morton et al., 2013; Wu et al., 2014; 
Yoshihara et al., 2010). Blood samples were taken from the tail vein and blood glucose 
measured using a glucometer (Abbott Diabetes Care, Alameda, CA) at 0 (fasting), 30, 60 and 
120 min after glucose administration. 
 
4.2.4 Central leptin sensitivity test 
After intraperitoneal teasaponin treatment for 21 days, mice were anaesthetised and placed in a 
stereotactic device. A intracerebroventricular (icv) cannula was implanted into the right lateral 
brain ventricle (0.25 mm posterior and 1.0 mm lateral relative to Bregma and 2.5 mm below 
the surface of the skull) (Paxinos and Franklin, 2002). Five days after implantation, mice were 
fasted for 6 hours and administered either leptin (0.1 µg/3 µl) or saline (3 µl) injected into the 
lateral ventricle through the cannula. Food intake and body weight were measured 24 hours 
after the leptin or vehicle injection to examine central leptin sensitivity.  
 
4.2.5 Blood and tissue collection 
Four days after the first central leptin sensitivity test, the mice received a second icv leptin or 
saline injection and were sacrificed one hour later. Plasma and brain tissue were collected and 
stored at -80 °C for further analyses as detailed below. 
 
4.2.6 Measurement of plasma leptin and insulin 
Plasma leptin and insulin were measured using the mouse metabolic magnetic bead panel kit 
(Merck Millipore, MA, USA). 
 
4.2.7 Western blot analysis 
Protein expression in frozen prefrontal cortex (equivalent to the prelimbic cortex, PrL, 
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dissected at the level of Bregma 2.8 mm to 1.98 mm) was determined using western blot as 
described in our previous study (Yu et al., 2013). The following antibodies were used: TNF-α 
(sc-8301), IL-1β (sc-7884) and IL-6 (sc-7920), BDNF, TrkB 145 and 95, pJAK2 and pAkt 
(Santa Cruz, CA, USA); pTrkB 95 (Sigma-Aldrich, St Louis, MO, USA); and p-IKK 
(Ser176/180) (#2697), p-IκBα (Ser32) (#2859), pSTAT3, pGSK3β and pFOXO1 (Cell 
Signaling Technology, Beverly, MA, USA). Bands corresponding to the proteins of interest 
were scanned and band density analysed using the Quantity One automatic imaging analysis 
system (Bio-Rad Laboratories, Hercules, CA, USA). All quantitative analyses were normalised 
to β-actin, based on our previous studies (Yu et al., 2013). Due to the small amount of tissue in 
the prefrontal cortex, we used a previously described modified multi-strip western blot 
(Kiyatkin and Aksamitiene, 2009; Yu et al., 2013). 
 
4.2.8 Oral teasaponin treatment and the novel object recognition test 
Mice were placed on a HFD for 8 weeks. The animals were then randomized into two groups, 
continuation of HFD for 6 weeks, or HFD with 0.5% teasaponin for 6 weeks. Age-matched, LC 
diet control mice were maintained on the lab chow diet. A novel object recognition test was 
performed 5 weeks after commencing teasaponin treatment.  
This test is based on the innate tendency of rodents to differentially explore novel objects over 
familiar ones as previously described (Arqué et al., 2008), with minor modifications. In brief, 
the experimental procedure consisted of habituation, training and retention sessions. On day 1, 
for habituation, mice were placed into an open-field box (55×55cm × 35cm high) for 10 
minutes with a 40 W light bulb in a sound proof room. On day 2, during the training session, 
two identical objects (A) were placed at opposing corners of the box, 5cm from the adjacent 
wall. Each mouse was then placed in the middle of the open-field box and left to explore the 
objects for 10 minutes. Ninety minutes later, in the retention session, one familiar object (A) 
was replaced with one novel object (B). Each mouse was placed in the middle of the open-field 
box, and left to explore for another 10 minutes. The exploration time for the familiar and the 
new objects was recorded. Memory was operationally defined by the discrimination index for 
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the novel object (DI) as the proportion of time animals spent investigating the novel object 
minus the proportion spent investigating the familiar one in the testing period in the retention 
session [Discrimination Index = (Novel Object Exploration Time/Total Exploration Time)–
(Familiar Object Exploration Time/Total Exploration Time)×100].  
 
4.2.9 Prefrontal cortical neuronal cultures and treatment 
Prefrontal cortical neuronal cultures were prepared from postnatal day 1 mice as described 
previously (Hilgenberg and Smith, 2007). Cells were plated at a final density of 5 × 10
5
/cm
2
 
into Poly-D-Lysine-coated 24-well culture plates for RT-PCR analysis. For neurogenesis 
imaging, cortical neurons were cultured on Poly-D-Lysine-coated coverslips. At 7 days in 
vitro, teasaponin (40µM) and/or palmitic acid (10 µM , P5585, Sigma-Aldrich) were added to 
the cultures. The method for dissolving palmitic acid was as described by Ross et al (Ross et 
al., 2010). Four hours after palmitic acid and/or teasaponin pre-exposure, leptin (100 ng/ml) or 
vehicle was added to the cultures for another 44 hours before the cells were harvested. 
 
4.2.10 Immunofluorescence and image analysis 
For immunocytochemical staining, neurons were fixed with 4% paraformaldehyde and 4% 
sucrose in Dulbecco's PBS for 20 min at room temperature. The samples were incubated with 
PBS containing 0.2% Triton X-100 for 5 min, and blocked with 10% horse serum in PBS for 1 
h at 37 °C. Then, the anti-BDNF antibody and anti-microtubule-associated protein 2 (MAP2) 
and antibody were applied overnight at 4 °C. BDNF was visualized with isotype-specific 
donkey anti-rabbit secondary antibody conjugated with Alexa Fluor 488; MAP2 was visualized 
by goat anti-mouse IgG (H+L) secondary antibody conjugated to Alexa Fluor 594. A 
fluorescence microscope (Axiovert 200, Carl Zeiss, Oberkochen, Germany) with an attached 
digital camera was used to obtain MAP2 immunofluorescence images for neuronal morphology 
analysis. A confocal microscope (Leica TCS SP5 Advanced System, Wetzlar, Germany) 
equipped with a digital camera was used to obtain images for immunofluorescence image of 
BDNF. 
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4.2.11 Neurite outgrowth and branching analysis.  
The quantification of neuronal morphology included: average neurite length, neurite length per 
cell, neurite number per cell, branches per neurite, and branches per cell. Experiments were 
independently performed three times, with each time repeated in triplicate (n=9). The image 
analysis was based on these nine repeats.  
 
4.2.12 Statistical analysis 
Data were analysed using the SPSS 19 statistical package (SPSS, Chicago, IL, USA). One-way 
analysis of variance (ANOVA) and the post-hoc Tukey-Kramer honestly significant difference 
(HSD) test were used to analyse the novel recognition test, body weight, and the glucose 
tolerance test and leptin signaling of the LC, HF, and teasaponin treatment groups in response 
to saline and leptin, as well as data from the cell culture experiments. A p value < 0.05 was 
regarded as statistically significant. Values are expressed as meanSEM. 
 
4.3 Results 
4.3.1 Teasaponin reduced body weight and food intake in obese mice 
When teasaponin was administrated via ip injection to HFD-induced obese mice it significantly 
reduced body weight and food intake during the 21-day observation period (Fig. 1A and 1B). 
The final body weight and average energy intake of the teasaponin group was also significantly 
lower than the HF control group following treatment (final body weight: -11.05%, p = 0.004; 
average energy intake: -24%, p < 0.001, Fig. 1A and 1C).  
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Fig. 1 Chronic administration of teasaponin (TS, 10 mg/kg ip for 21 days) significantly decreased body 
weight (A), daily food intake (B) and average energy intake (C) in obese mice (n=16) fed a high-fat (HF) 
diet for 16 weeks. *p<0.05 vs. HF control group. 
 
4.3.2 Teasaponin improved glucose tolerance, blood hormone profiles and discrimination 
index 
Glucose tolerance tests were performed to assess glucose homeostasis and insulin sensitivity in 
HFD-induced obese mice treated with teasaponin. Blood glucose levels were lower at the 30 
and 60 minute time points in the teasaponin treatment group compared to the HF controls 
during the glucose tolerance test (Fig. 2A). The teasaponin treatment also decreased HOMA 
(Fig. 2B), indicating that it reduced insulin resistance in the HFD-induced obese mice. HFD-
induced hyperinsulinemia and hyperleptinemia were significantly reversed by teasaponin 
treatment (Fig. 2C and 2D). Teasaponin attenuated HF-induced decline in discrimination index 
reflecting recognition memory in the novel object recognition test in mice (Fig. 2E). 
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Fig. 2 Chronic administration of teasaponin improved glucose tolerance (A) and HOMA (B), decreased 
plasma insulin (C) and leptin (D) in obese mice (n=8) fed a high-fat (HF) diet for 16 weeks. *p<0.05 vs. 
HF control group. The homeostasis model assessment of insulin sensitivity (HOMA) is calculated by 
(fasting glucose [mmol/l] multiplied by fasting insulin [U/ml] divided by 22.5). (E) Teasaponin 
attenuated HF-induced decline in discrimination index reflecting recognition memory in the novel object 
recognition test in mice. Discrimination Index = (Novel Object Exploration Time / Total Exploration 
Time) – (Familiar Object Exploration Time / Total Exploration Time) × 100. * p<0.05 vs. HF fed mice. 
Data are presented as mean±SEM, n=10. LC: lab chow diet fed mice. 
 
4.3.3 Teasaponin attenuated hypothalamic inflammation and improved central leptin 
sensitivity and leptin signaling 
Western blot analysis showed that in the mediobasal hypothalamus, a HFD elevated TNF-α, 
IL-6, p-IKK and SOCS3 protein expression, which was significantly decreased by treatment 
with teasaponin (Fig. 3A, 3B, 3D, and 3E). We also evaluated if leptin signaling in the CNS 
improved in conjunction with the observed reduction in hypothalamic inflammation. Leptin 
administered icv significantly decreased energy intake for 24 hours in LC diet fed mice (-40%, 
p < 0.001; Fig 4A), but not in HFD fed animals (-18%, p = 0.421; Fig. 4B). While energy 
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intake was significantly decreased in the teasaponin-treated mice receiving icv injections of 
leptin compared with the icv injection of saline (-31%, p=0.023; Fig. 4B).  
To clarify the mechanisms underlying the enhanced effect of leptin in the teasaponin-treated 
mice, we measured p-STAT3 protein levels in the mediobasal hypothalamus after the chronic 
treatment with teasaponin and leptin stimulation. Leptin administered icv significantly 
increased p-STAT3 in LC diet fed mice (p < 0.001; Fig. 4C), while p-STAT3 did not 
significantly increase in response to the leptin injection in control HFD-induced obese mice 
(Fig. 4D). With the teasaponin treatment, the p-STAT3 level significantly increased after icv 
leptin injection compared with icv saline (94%, p < 0.001) (Fig. 4D). 
 
Fig. 3 Effect of chronic teasaponin treatment on the protein levels of inflammatory markers in the 
mediobasal hypothalamus of obese mice fed a high-fat (HF) diet for 16 weeks. Chronic treatment of 
teasaponin significantly decreased the level of the pro-inflammatory cytokines TNF-α (A), IL-6 (B) and 
IL-1β (C), as well as the inflammatory signaling molecules p-IKK (D) and SOCS3 (E). n=6-8, *p<0.05 
vs HF group. 
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Fig. 4 Energy intake (EI) at 1, 4 and 24 hours after the icv injection of leptin or saline in low-fat (LC) 
diet fed mice (n=7-8) (A), in obese mice fed a high-fat (HF) diet for 16 weeks with or without chronic 
treatment of teasaponin (10 mg/kg ip daily for 21 days) (n=6-8) (B). STAT3 phosphorylation in the 
mediobasal hypothalamus 1 hour after the icv injection of leptin or saline in LC diet fed mice (n=7-8) 
(C) and obese mice fed a high-fat diet for 16 weeks with or without chronic treatment of teasaponin 
(n=6-8) (D). *p<0.05 vs. icv injection of saline within the treatment group (LC, HF control, or HF with 
TS treatment); 
#
p<0.05 vs. HF group (vehicle) with an icv injection of leptin; 
+
p<0.05 vs. HF group 
(vehicle) with an icv injection of saline. 
 
4.3.4 Teasaponin restored leptin-pJAK2-pSTAT3 signaling and improved leptin-
mediated BDNF expression in the prefrontal cortex of HF fed mice 
Several molecules, including JAK2-STAT3 and Akt-FOXO1/GSK, have been established as 
downstream mediators of leptin signaling in the hypothalamus (Benzler et al., 2013; Kim et al., 
2006; Morton et al., 2005). Here we examined the leptin signaling pathways JAK2-STAT3 and 
Akt-FOXO1/GSK in the prefrontal cortex. An icv injection of leptin significantly increased 
pJAK2 in the prefrontal cortex of LC mice (p<0.001), but not in HF fed mice (p>0.05, Fig. 
5A). However, with teasaponin treatment, the leptin injection significantly increased pJAK2 in 
HF fed mice compared to saline injection (p<0.05). There was a similar response in the 
pSTAT3, downstream step of leptin/pJAK2 signaling in the LC, HF and teasaponin-treated HF 
mice (Fig. 5B). Leptin significantly increased pSTAT3 by 42% in the prefrontal cortex of LC 
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mice, while in HF fed mice pSTAT3 only increased by 16% after the leptin injection. 
Following chronic teasaponin treatment, pSTAT3 increased by 46% in response to leptin 
compared with the saline injection, suggesting that teasaponin improved leptin-pJAK2-
pSTAT3 signaling in HF fed mice. We also found that leptin significantly increased pAkt, 
pGSK3β and pFOXO1 in the prefrontal cortex of LC but not in HF fed mice (p<0.05, Fig. 5C-
E). However, teasaponin treatment did not reverse impaired leptin-pAkt-pGSK3β/pFOXO1 
signaling in HF fed mice.  
 
Fig. 5 Effect of teasaponin treatment (TS, 10mg/kg, ip for 21 days) on leptin-pJAK2-pSTAT3 signaling 
(A, B), pAkt-pGSK3β/pFOXO1 (C-E) and leptin-BDNF in the prefrontal cortex of high-fat diet (HF) fed 
mice. *p<0.05 vs. saline in individual group. Data are presented as mean±SEM, n=8–9. LC: lab chow 
diet fed mice. 
 
4.3.4 Teasaponin improved leptin-mediated BDNF expression in the prefrontal cortex of 
HF fed mice and cultured prefrontal cortical neuron 
After icv leptin injection, the BDNF level in the prefrontal cortex was significantly increased in 
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LC mice (p<0.05), but not in HF fed mice (Fig. 5F). Importantly, with chronic teasaponin 
treatment, leptin increased BDNF levels compared to saline in the prefrontal cortex of HF fed 
mice, suggesting that teasaponin treatment improved the leptin-induced increase in BDNF in 
the prefrontal cortex. However, teasaponin treatment did not significantly alter basal BDNF 
protein levels in HF mice (p>0.05).  
In cultured prefrontal cortical neurons, immunostaining with ani-BDNF antibody showed a 
granula distribution of BDNF in MAP2-positive neurons (Fig. 6A). Leptin treatment 
significantly increased BDNF expression, evidencing by the strong immunoreactivity (Fig. 6B) 
and substantial increase in mRNA expression (2.5-fold, p<0.05, Fig. 6C). However, following 
palmitic acid pretreatment, leptin did not increase BDNF expression (Fig. 6B and 6C). This 
suggests palmitic acid inhibits leptin stimulation of BDNF in prefrontal cortex neurons. 
Importantly, teasaponin treatment significantly increased leptin-mediated BDNF mRNA 
expression (p < 0.05, Fig. 6C) and immunoreactivity (Fig. 6B) in palmitic acid pre-treated 
cortical neurons. Interestingly, teasaponin treatment also induced a significant increase in basal 
BDNF expression (i.e. without leptin) in cortical neurons (Fig. 6B and 6C). 
 
Fig. 6 Teasaponin improved leptin-mediated BDNF expression in the cultured prefrontal cortical 
neuron. Immunocytochemistry images showing the typical BDNF-containing vesicles (indicated by 
white arrowheads), taken by confocal microscope (Nikon) (A); Palmitic acid (PA) decreased leptin-
induced BDNF immunoreactivity (B) and mRNA expression (C) in cultured prefrontal cortical neurons, 
which can be corrected by teasaponin (TS) (B and C);   TS and leptin significantly increased BDNF 
immunoreactivity in cortical neurons (B). Pretreatment with PA significantly inhibited leptin-induced 
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BDNF (B and C); TS prevented PA from inhibiting the leptin-induced stimulation of BDNF. Data 
expressed as mean ± SEM (n = 6, obtained from six independent culture wells). *p < 0.05. Leptin (100 
ng/mL) was applied to the neuron cultures 4 hours after pre-treated with PA and/or TS, then lasted for 
44-h exposure.  Scale bar = 50 μm. TS: teasaponin; PA: palmitic acid. 
 
4.3.5 Teasaponin promoted neurite outgrowth in response to leptin in cultured prefrontal 
cortical neurons 
We examined the effect of teasaponin on neurite outgrowth in cells treated with leptin and 
palmitic acid (Fig. 7A and 7B). Morphological analyses showed that leptin significantly 
increased the average neurite length (Fig. 7D) and total neurite length per cell (Fig. 7E) in 
control cortical neurons, but not in palmitic acid treated neurons. Whereas with teasaponin pre-
treatment, leptin increased average neurite length (45%, p<0.05, Fig. 7D) and total neurite 
length per cell (45%, p<0.05, Fig. 7E) compare to saline, suggesting teasaponin attenuated the 
effect of palmitic acid on leptin-induced neurite length. However, the neurite number per cell in 
cortical neurons was not affected by leptin, PA or teasaponin (Fig. 7F). Furthermore, leptin 
treatment significantly increased neurite branching (branches per neurite: +59%, Fig. 7G, 
branches per cell: +59%, Fig. 7H) compared with saline treatment in control neurons, but not in 
palmitic acid treated neurons. With teasaponin pretreatment, leptin significantly increased 
branches per neurite, but not branches per cell. The mRNA expression of MAP2, a neurite 
marker, was also examined by RT-PCR. Teasaponin prevented palmitic acid from inhibiting 
the leptin-induced stimulation of MAP2 mRNA (Fig. 7I). 
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Fig. 7 Effect of teasaponin (TS) and palmitic acid (PA) on the leptin-induced neurite 
outgrowth. A: represents fluorescence images obtained under Confocal Microscope (Nikon), 
scale bar = 50 μm; B: an example of MAP2 immunofluorescence staining image (8 bit) used 
for neuron morphology analysis, scale bar = 100 μm; C: an example of analysis tracing of 
neuron morphology quantification by using NeuriteQuant toolkit. All parameters (D-H) used 
were automatically analysed and calculated by the algorithm of NeuriteQuant in pixels, n=9; D: 
Average neurite length; E: Neurite length per cell; F: Neurite number per cell; G: Branches per 
neurite; H: Branches per cell; I: MAP2 mRNA expression measured by qRT-PCR (n=5-7). 
*p<0.05 vs. saline in individual group. Data are presented as mean ± SEM. Leptin (100 ng/ml) 
was applied to the neuron cultures 4 hours before 44 hour exposure to TS (20 or 40µM) or 
palmitic acid (10 µM). 
 
4.4 Discussion: 
This study demonstrated that teasaponin treatment reduced obesity, hypothalamic 
inflammation, and central leptin resistance in high-fat (HF) diet-induced obese mice. The anti-
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inflammatory effects of teasaponin were associated with an improved glycemic status in the 
treated animals, evidenced by improved glucose tolerance, HOMA and fasting plasma insulin. 
Furthermore, teasaponin decreased pro-inflammatory cytokines and inflammatory signaling in 
the mediobasal hypothalamus, and enhanced the anorexigenic effect of central leptin 
administration as demonstrated by the restoration of p-STAT3 signaling in the mediobasal 
hypothalamus. Furthermore, chronic teasaponin treatment enhanced object recognition 
memory, and improved leptin signaling and leptin-induced BDNF expression in the prefrontal 
cortex of HF fed mice. Moreover, in cultured primary prefrontal cortical neurons, palmitic acid 
impaired the effect of leptin on neurite growth, and teasaponin ameliorated these palmitic acid 
induced effects.  
Leptin promotes negative energy balance by signaling in the brain, and the hypothalamus is a 
key region for the control of food intake by this hormone. This negative feedback loop 
becomes disrupted in most obese individuals, resulting in a state known as central leptin 
resistance. In this study we confirmed central leptin resistance in HFD induced obese mice. The 
icv injection of leptin significantly decreased food intake in LC control mice, but not in HF 
obese mice with hyperleptinemia. There are two mechanisms that explain central leptin 
resistance, hyperleptinemia (Knight et al., 2010) and hypothalamic inflammation (Thaler et al., 
2012; Zhang et al., 2008). Firstly, it is reported that hyperleptinemia is required for the 
development of leptin resistance in diet-induced obese mice (Knight et al., 2010). In the current 
study, teasaponin significantly reduced body fat and dramatically ameliorated hyperleptinemia 
induced by HFD-induced obesity. This may have reduced the overstimulation of the leptin 
receptor and downstream signaling, thus improving central leptin sensitivity. Secondly, recent 
studies have revealed that hypothalamic inflammation can mediate central leptin resistance in 
HFD-induced obese rodents (Thaler et al., 2012; Zhang et al., 2008). Constitutive activation of 
IKKβ in the hypothalamus of mice induced central leptin resistance and impaired leptin 
signaling through p-STAT3 (Zhang et al., 2008). In contrast, a genetic or pharmacological 
blockade of inflammatory signaling in the hypothalamus improved leptin sensitivity and 
elevated p-STAT3 (Milanski et al., 2012; Zhang et al., 2008). In mice with an IKK knockout in 
 
Yizhen Wu                                                                                                                                                 77 
 
hypothalamic AgRP neurons, the level of p-STAT3 was significantly increased in response to 
icv administered leptin in animals fed a HFD (Zhang et al., 2008). In this study, teasaponin 
decreased the expression of the hypothalamic pro-inflammatory cytokines and inflammatory 
signaling molecules, such as TNF-α, IL-6, IL-1β and p-IKK. This may have contributed to the 
improved leptin sensitivity and hypothalamic leptin signaling via p-STAT3 following the 
teasaponin treatment in the diet-induced obese mice.  
SOCS3 has been identified as a negative regulator of central leptin signaling. The 
overexpression of SOCS-3 results in the inhibition of leptin signaling through JAK2/STAT3 
(Bjørbæk et al., 1999). Negative feedback in response to excessive hormone stimulation is a 
classical mechanism of hormone resistance. It is known that leptin stimulates the expression of 
SOCS3, which directly inhibits leptin signaling in the hypothalamus (Bjørbæk et al., 1998). 
Furthermore, overexpression of IKK in the hypothalamic neurons of mice increases SOCS3 
mRNA expression and protein levels in the hypothalamus (Zhang et al., 2008). Therefore in the 
current study, hyperleptinemia and hypothalamic inflammation in diet-induced obese mice may 
activate a common negative regulator of leptin signaling, SOCS3, and contribute to central 
leptin resistance. Upregulation of SOCS3 in POMC neurons leads to impairment of STAT3 
signaling, with subsequent leptin resistance, obesity, and glucose intolerance (Reed et al., 
2010). In contrast, hypothalamic SOCS3-deficient rats exhibited enhanced leptin-induced 
STAT3 activation, decreased body weight gain and improved metabolic parameters when 
exposed to a high-fat diet (Liu et al., 2011b). In the present study, teasaponin significantly 
decreased the level of SOCS3 in the hypothalamus of HF induced obese mice, suggesting that 
SOCS3 is a potential target for teasaponin’s therapeutic intervention during obesity. 
In the present study, central acute administration of leptin significantly increased its 
downstream signaling molecule, pJAK2 and pSTAT3 in the prefrontal cortex of control mice. 
In accordance with our results, another study demonstrated that systemic administration of 
leptin activated STAT3 phosphorylation in cortical neurons, in a rat model of cerebral ischemia 
(Amantea et al., 2011). We also have demonstrated that leptin activates pAkt, pFOXO1 and 
pGSK3β, another leptin signaling pathway, in the prefrontal cortex of LC mice. In obesity 
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plasma leptin is increased, which theoretically will prevent overeating and obesity. However, 
this is not the case as leptin resistance is a pathology of obesity (Myers et al., 2008a). 
Furthermore, obese subjects with hyperleptinemia have an increased prevalence of dementia 
and other neurodegenerative disease (Carpenter et al., 2000; Carter et al., 2000; Lieb et al., 
2009b). Therefore, it is unlikely that high plasma leptin levels will appropriately activate 
signaling pathways in the brain of obese individuals with leptin resistance. Indeed, our results 
showed that, in HF fed obese mice, both the leptin-pJAK2-pSTAT3 and pAkt-
pGSK3β/pFOXO1 signaling pathways were impaired in the prefrontal cortex. Importantly, 
teasaponin treatment corrected alteration of the leptin-pJAK2-pSTAT3 signaling pathway in 
the prefrontal cortex of HF fed mice. It has been reported that leptin replacement improves 
cognition in leptin-deficient patients with a delay or decline of cognitive function (Paz-Filho et 
al., 2008). The prefrontal cortex is important for cognitive control (Cole et al., 2012a), and HF 
reduces synaptic plasticity in this region (Val-Laillet et al., 2011b) leading to learning and 
memory impairments (Laroche et al., 2000a). Therefore, teasaponin may attenuate HF induced 
impairments of leptin signaling in the prefrontal cortex, leading to improved recognition 
memory. 
In the prefrontal cortex, BDNF promotes neuronal plasticity and neurogenesis, which are 
important for learning and memory (Kanoski et al., 2007b; Sakata et al., 2013a). HFD reduced 
BDNF in the prefrontal cortex and impaired discrimination reversal learning in rats (Kanoski et 
al., 2007b). A continuous icv infusion of antisense BDNF oligonucleotide resulted in an 
impairment of spatial learning in rats, with a significant reduction of BDNF mRNA and protein 
levels in the brain (Mizuno et al., 2003). In the clinic, it is reported that BDNF levels in plasma 
are positively correlated to memory performance in patients with depression (Grassi-Oliveira et 
al., 2008). Leptin administration has been shown to increase BDNF expression in the 
hippocampus of mice, which can be blocked by pre-treatment with K252a, a blocker of the 
BDNF receptor (Yamada et al., 2011). In this study, we observed that leptin stimulated BDNF 
expression in the prefrontal cortex of control mice, but not in HF fed obese mice. In cultured 
primary prefrontal cortical neurons, leptin increased neurite outgrowth, however, this effect 
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was impaired by palmitic acid. Along with improving the leptin-pJAK2-pSTAT3 signaling 
pathway, our results demonstrated a beneficial effect of teasaponin on the upregulation of 
BDNF and neurite outgrowth by leptin. These results suggest that teasaponin-induced 
activation of leptin signaling may have modulated BDNF expression, enhancing neurite 
outgrowth in the prefrontal cortex and contributing to an improvement in recognition memory. 
In summary, we have demonstrated that chronic teasaponin treatment significantly reduced 
food intake and body weight in HFD-induced obese mice. Treatment with teasaponin 
significantly ameliorated central inflammation by reducing pro-inflammatory cytokines and 
inflammatory signaling molecules in the hypothalamus. Therefore, teasaponin has important 
effects in improving glucose tolerance, central leptin sensitivity and hypothalamic leptin 
signaling. These results identify a novel role for teasaponin as an anti-obesity and anti-
inflammatory agent. Furthermore, teasaponin improved recognition memory in the HF fed 
mice. Through in vivo and in vitro studies we revealed that leptin activated leptin-pJAK2-
pSTAT3 and pAkt-pFOXO1/pGSK3β signalling, stimulated BDNF expression and neurite 
outgrowth in the prefrontal cortex. However, these prefrontal cortex responses are impaired 
when mice are fed a high-saturated fat diet, or neurons exposed directly to saturated fatty acid, 
i.e. palmitic acid in vitro. Teasaponin treatment ameliorates alteration of leptin-pJAK2-
pSTAT3 and leptin-BDNF in the prefrontal cortex of HF fed mice. Treatment with teasaponin 
also promoted leptin’s effect on neurite outgrowth in prefrontal cortical neurons. Since high fat 
diet-induced obesity has been implicated in the progression of neurodegenerative diseases, such 
as vascular dementia, teasaponin supplementation may have beneficial effects in attenuating 
the progression of cognitive decline in obese patients and reducing the risk of 
neurodegenerative diseases. The dose of teasaponin obtained by frequently drinking tea is 
significantly lower than the doses used in this rodent study. In order to reach the effect 
observed in this study, a supplemental delivery of teasaponin (oral or injection) would be 
needed. Clinical trials would also be required to determine the optimum dose in humans. 
Furthermore, the potential toxicity of long-term teasaponin exposure should be investigated 
before teasaponin supplementation can be recommended. 
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SUPPLEMENTARY DATA 
Table S1. The antibodies used in this study 
Peptide/protein 
target 
Name of Antibody Manufacturer, catalog # Species raised in monoclonal or 
polyclonal 
Dilution used 
TNFα TNFα Antibody (H-156) Santa Cruz Biotechnology, sc-8301 rabbit, polyclonal 1:200 
IL-6 IL-6 Antibody (H-183) Santa Cruz Biotechnology, sc-7920 rabbit, polyclonal 1:200 
IL-1β IL-1β Antibody (H-153) Santa Cruz Biotechnology, sc-7884 rabbit, polyclonal 1:200 
pIKK Phospho-IKKα/β (Ser176/180) 
(16A6) Rabbit mAb 
Cell Signaling Technology, #2687  1:1000 
SOCS3 SOCS3 (L210) Antibody Cell Signaling Technology, #2932  1:1000 
BDNF BDNF (H-117) Santa Cruz Biotechnology, sc-20981 Rabbit, Polyclonal 1:400 
TrkB 145 and 95 TrkB (H-181) Santa Cruz Biotechnology, sc-8316 Rabbit, Polyclonal 1:500 
pTrkB 95 Anti-phospho-Trk B (pTyr705) Sigma-Aldrich, SAB4503786 Rabbit, Polyclonal 1:500 
p-JAK2 p-JAK2 (Tyr 1007/Tyr 1008) Santa Cruz Biotechnology, sc-21870 Goat, Polyclonal 1:500 
p-STAT3 Phospho-Stat3 (Tyr705) (D3A7) 
XP
®
 Rabbit mAb 
Cell Signaling Technology, #9145 Rabbit, Monoclonal 1:2000 
pAkt p-Akt1/2/3 (Ser 473)-R Santa Cruz Biotechnology, sc-7985-R Rabbit, Polyclonal 1:500 
pGSK3β Phospho-GSK-3β (Ser9)(5B3) 
Rabbit mAb 
Cell Signaling Technology, #9323 Rabbit, Monoclonal 1:1000 
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 Continued Table S1.    
Peptide/protein 
target 
Name of Antibody Manufacturer, catalog # Species raised in monoclonal or 
polyclonal 
Dilution used 
BDNF BDNF Antibody (H-117) Santa Cruz Biotechnology, sc-20981 Rabbit, Polyclonal 1:100 
MAP2 Monoclonal Anti-MAP2 antibody  Sigma-Aldrich, #M4403 Mouse, Monoclonal  1:500 
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Table S2. The primers used in qPCR for mRNA measurement of neurogenesis markers  
GENE Forward primer Reverse primer NCBI reference 
BDNF GGGTCACAGCGGCAGATAAA GCCTTTGGATACCGGGACTT NM_001285416.1 
MAP2 ATGAAGGAAAGGCACCACAC AATAGGTGCCCTGTGACCTG NM_001039934.1 
γ-actin GCTAACAGAGAGAAGATGACG CAGATGCATACAAGGACAGC NM_009609.2 
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CHAPTER FIVE 
5.1   Overall Discussion and conclusions 
The prevalence of obesity is a worldwide health problem, and it is an important risk factor for 
the development of type 2 diabetes, cardiovascular disease, and certain cancer, as well as 
depression, and neurodegenerative diseases. Obesity features as weight gain, fat deposition, and 
energy homeostasis imbalance, obesity-associated central and peripheral inflammation, central 
and peripheral leptin resistance, blunt leptin signaling, as well as obesity-associated 
neurodegeneration and cognitive decline. Addressing these features issues will help to anti-
obesity, and reduced the risks of obesity-linked diseases. A chronic low-grade inflammatory 
state during obesity is at the pathogenic core of obesity and type 2 diabetes. Therefore, it is 
essential to develop novel therapeutic agents that have the ability of anti-obesity-associated 
inflammation. Triterpene saponins, are groups of pant secondary metabolites with structurally 
composed of a lipid soluble aglycone and a water soluble sugar residues. The amphiphilic 
nature of the triterpene saponins suggests that they can intercalate into the cell membrane to 
mediate the cellular events. Some plant-derived triterpene saponins are anti-inflammatory and 
inhibit the NF-κB signaling pathway. In this study, ginsenoside Rb1, one of the triterpene 
saponins, has been reported to have anti-inflammation and neuroprotective effect, has been 
implicated to treat the central leptin resistance, obesity-associated inflammation, and glucose 
intolerance, as well as to investigate whether it could improve leptin effects on BDNF, 
synaptogenesis in the prefrontal cortical neurons of obese, using an in vivo and in vitro model. 
Teasaponin, active ingredient derived from tea, has recently been showed anti-inflammation 
properties. This study was to evaluate its effects on obesity, obesity-associated hypothalamic 
inflammation, hypothalamic and cortical leptin sensitivity of the high-fat diet-induced obese 
mice, as well as leptin-mediated BDNF expression and neurite outgrowth in the prefrontal 
cortical neurons, using an in vivo and in vitro model. 
► Central Inflammation and Leptin Resistance Are Attenuated by Ginsenoside Rb1 
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Treatment in Obese Mice Fed a High-Fat Diet 
A low-grade pro-inflammatory state is at the pathogenic core of obesity and type 2 diabetes. We 
tested the hypothesis that the plant terpenoid compound ginsenoside Rb1 (Rb1), known to exert 
anti-inflammatory effects, would ameliorate obesity, obesity-associated inflammation and 
glucose intolerance in the high-fat diet-induced obese mouse model. Furthermore, we examined 
the effect of Rb1 treatment on central leptin sensitivity and the leptin signaling pathway in the 
hypothalamus. We found that intraperitoneal injections of Rb1 (14mg/kg, daily) for 21 days 
significantly reduced body weight gain, fat mass accumulation, and improved glucose tolerance 
in obese mice on a HFD compared to vehicle treatment. Importantly, Rb1 treatment also 
reduced levels of pro-inflammatory cytokines (TNF-α, IL-6 and/or IL-1β) and NF-κB pathway 
molecules (p-IKK and p-IκBα) in adipose tissue and liver. In the hypothalamus, Rb1 treatment 
decreased the expression of inflammatory markers (IL-6, IL-1β and p-IKK) and negative 
regulators of leptin signaling (SOCS3 and PTP1B). Furthermore, Rb1 treatment also restored 
the anorexic effect of leptin in high-fat fed mice as well as leptin pSTAT3 signaling in the 
hypothalamus. Ginsenoside Rb1 has potential for use as an anti-obesity therapeutic agent that 
modulates obesity-induced inflammation and improves central leptin sensitivity in HFD-
induced obesity. 
► Ginsenoside Rb1 improves leptin sensitivity in the prefrontal cortex in obese mice 
Obesity impairs leptin-induced regulation of brain-derived neurotrophic factor (BDNF) 
expression and synaptogenesis, which has been considered to be associated with the incidence 
of neuronal degenerative diseases, cognitive decline and depression. Ginsenoside Rb1 (Rb1), a 
major bioactive component of ginseng, is known to have an anti-obesity effect and improve 
cognition. This study examined whether Rb1 can improve central leptin effects on BDNF 
expression and synaptogenesis in the prefrontal cortex during obesity using an in vivo and an in 
vitro model. Rb1 chronic treatment improved central leptin sensitivity, leptin-JAK2-STAT3 
signaling and leptin-induced regulation of BDNF expression in the prefrontal cortex of high-fat 
diet induced obese mice. In cultured prefrontal cortical neurons, palmitic acid, the saturated fat, 
impaired leptin-induced BDNF expression, reduced the immunoreactivity and mRNA 
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expression of synaptic proteins, and impaired leptin-induced neurite outgrowth and 
synaptogenesis. Importantly, Rb1 significantly prevented these pernicious effects induced by 
palmitic acid. These results indicate that Rb1 reverses central leptin resistance and improves 
leptin-BDNF-neurite outgrowth and synaptogenesis in the prefrontal cortical neurons. Thus, 
Rb1 supplementation may be a beneficial avenue to treat obesity-associated neurodegenerative 
disorders.  
► Teasaponin improves hypothalamic and cortical leptin sensitivity in diet-induced obese 
male mice 
Hypothalamic inflammation is involved in the pathogenesis of obesity and type 2 diabetes. 
Obesity impairs cognition, and the leptin-induced increase of brain-derived neurotrophic factor 
(BDNF) and neurogenesis. Tea consumption improves inflammation, cognition and increases 
brain activation in the prefrontal cortex. This study examined whether teasaponin, an active 
ingredient in tea, could improve central inflammation and leptin sensitivity in the hypothalamus 
and prefrontal cortex of obese mice. Teasaponin (10mg/kg, intraperitoneal) for 21 days 
significantly decreased the food intake and body weight of high-fat (HF) diet-induced obese 
mice. In the hypothalamus teasaponin decreased both pro-inflammatory cytokines and 
inflammatory signaling in the mediobasal hypothalamus. Teasaponin treatment also enhanced 
the anorexigenic effect of central leptin administration, restored leptin p-STAT3 signaling in the 
hypothalamus. Furthermore, teasaponin improved downstream leptin signaling (JAK2, and 
STAT3), and leptin’s effect on BDNF, in the prefrontal cortex of HF fed mice. Prefrontal 
cortical neurons were cultured with teasaponin and palmitic acid (the most abundant dietary 
saturated fatty acid) to examine their effects on BDNF and neurite outgrowth in response to 
leptin. Palmitic acid decreased leptin’s effect on BDNF and neurite outgrowth in cultured 
cortical neurons, which were reversed by teasaponin. Therefore, teasaponin supplementation 
may be used to prevent obesity-associated neurodegeneration and improve cognitive function.  
This chapter will provide a general discussion and conclusions of the present PhD research 
project undertaken. The main findings of this thesis are summarized in Table 5.1. Detailed 
discussion of each study has been included in the discussion section at the end of chapter 2-4, 
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while overall discussion of the findings is included in section 5.1.1. The proposed potential 
treatment mechanisms of triterpene saponins are included in section 5.1.2 (Figure 5.1). The 
conclusions of the thesis are presented in section 5.1.3. Based on the research outcomes of the 
present project and the related existing knowledge, recommendations of future research are 
included in section 5.1.4. 
Table 5.1 The main finding of this project (Chapter 2-4)                                                                                          
-------Effects of Triterpene Saponins treatment 
Parameters/ Reference 
Effect of Rb1 
(Wu et al., 2018; 
Wu et al., 2014) 
Effect of Teasaponin 
(Yu et al., 2015; Yu et al., 
2013) 
In vivo (DIO mice) 
Food Intake (g) ↓ ↓ 
Body Weight Gain ↓ ↓ 
Final Body Weight NSD ↓ 
Fat Mass 
        Epididymal fat ↓ ↓ 
      Perirenal fat ↓ ↓ 
      Mesenteric fat 
 
↓ 
       Inguinal fat ↓ ↓ 
Adipocyte size ↓ ↓ 
Liver Weight NSD ↓ 
Plasma profile 
        Leptin ↓ ↓ 
      Insulin NSD ↓ 
      Adiponectin ↑ ↑ 
      PYY ↑ ↑ 
Neuropeptides 
        POMC ↑ ↑ 
      AgRP ↓ NSD 
      NPY NSD NSD 
Glucose Tolerance  Improved Improved 
       blood glucose at GTT 
             0 Minutes NSD ↓ 
          30 Minutes ↓ ↓ 
           60 Minutes ↓ ↓ 
           120 Minutes NSD ↓ 
Peripheral Inflammation 
  
    Liver 
  
          IL-6 ↓ ↓ 
          IL-1β NSD NSD 
          TNFα ↓ ↓ 
           pIKK  NSD ↓ 
          pIκBα NSD ↓ 
          SOCS3 ↓ (trend) NSD 
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Table 5.1 (Continued) 
Parameters/ Reference 
Effect of Rb1 
 (Wu et al., 2018; Wu et 
al., 2014) 
Effect of Teasaponin 
(Yu et al., 2015; Yu et 
al., 2013) 
    Epididymal fat 
 
 
          IL-6 ↓ NSD 
          IL-1β ↓ ↓ 
          TNFα ↓ ↓ 
           pIKK  ↓ ↓ 
          pIκBα ↓ (trend) ↓ 
Hypothalamic Inflammation   
          IL-6 ↓ ↓ 
          IL-1β ↓ ↓ 
          TNFα NSD ↓ 
           pIKK  ↓ ↓ 
          SOCS3 ↓ ↓ 
          PTP1B ↓   
Central leptin sensitivity   
    Acute treatment 
           4h EI ↓ ↓ 
         24h EI ↓ ↓ 
         24h BWG ↓ ↓ 
    Chronic treatment 
 
 
         4h EI ↓ ↓ 
         24h EI ↓ ↓ 
         24h BWG ↓ ↓ 
Hypothalamic leptin signaling  
          pSTAT3   ↑ ↑ 
         pFOXO1  NSD NSD 
Prefrontal cortex BDNF ↑ NSD 
Prefrontal cortex Leptin-BDNF ↑ ↑ 
Prefrontal cortex leptin signaling   
         pJAK2   ↑ ↑ 
         pSTAT3   ↑ ↑ 
         pAkt 
 
NSD 
         pGSK3β 
 
NSD 
         pFOXO1  
 
NSD 
In vitro (PA-treated primary cortical neurons) 
Leptin-mediated BDNF 
                 Immunoreactivity ↑ ↑ 
               mRNA  ↑ ↑ 
Leptin-mediated Neurite outgrowth 
                Branching ↑ ↑ 
              Length ↑ ↑ 
              MAP2 mRNA  ↑ ↑ 
Leptin-mediated synaptogenesis 
                 PSD95 Immunoreactivity ↑  (dendrite and soma)  ↑  
               PSD95 mRNA  ↑ ↑ 
               SYN Immunoreactivity ↑  (in dendrite) ↑ 
               SYN mRNA  NSD NSD 
Abbreviations: Rb1: ginsenoside Rb1; HFD: vs.: versus; high-fat diet; DIO: high-fat diet-induced obese; 
NSD: no significant difference; PYY: peptide YY; POMC: Proopiomelanocortin; AgRp: Agouti gene-
related peptide; NPY: Neuropeptide Y; GTT: glucose tolerance test; BG: blood glucose; IL-6: Interleukin 
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6; IL-1β: Interleukin-1β; TNFα: Tumor necrosis factor α; pIKK: ; pIκBα: ; SOCS3: Suppressor of 
Cytokine Signaling 3; PTP1B: Protein Tyrosine Phosphatase 1B; EI: energy intake; BWG: body weight 
gain; Ob: high-fat diet-induced obese mice; pJAK2: Phosphorylated Janus Kinase 2; pSTAT3: 
Phosphorylated Signal Transducer and Activator of Transcription; pAkt: Phosphorylated Protein kinase 
B; pGSK3β: Phosphorylated Glycogen synthase kinase-3; pFOXO1: Phosphorylated Forkhead box 
protein O1; PA: palmitic acid; TS: teasaponin; BDNF: brain-derived neurotrophic factor; PSD-95: ; SYN: 
synaptophysin. 
 
5.1.1 Overall discussion of findings 
In chapter 2, we reported Rb1 treatment decreased food intake, final body weight and reduced 
fat deposition in the high-fat diet-induced obese mice. These results are consistent with a 
previous report, which showed that Rb1 has an anti-obesity effect in rats and its suppression of 
food intake is not due to malaise, as attested by a conditioned taste aversion test (Xiong et al., 
2010). Rb1 reduced fat deposition mainly attributed by the decreased in the adipocyte size and 
the increased the number of small adipocytes and reduced the number of large adipocytes. 
Importantly, this study also extends the mechanism of Rb1 in suppressing food intake. Rb1 
treatment increased the anorexigenic hormone, peptide YY (PYY), in the blood and modulated 
hypothalamic neuropeptides, specifically by increasing anorexigenic POMC and decreasing 
orexigenic AgRP mRNA expression in the HFD-induced obese mice. Furthermore, this study 
reported Rb1 decreased the protein level of pro-inflammatory cytokines (TNFα, IL-6 and IL-1β) 
and inflammation signaling (pIKK) in the peripheral metabolic tissue, epididymal fat tissue and 
liver. Since peripheral inflammatory responses induced by over nutrition and obesity has been 
linked to decreases insulin sensitivity in target cells and contributed to glucose intolerance and 
development of type 2 diabetes (Cai et al., 2005; Stanton et al., 2011a; Weisberg et al., 2003; 
Xu et al., 2003), the anti-inflammation effect of Rb1 in the peripheral tissues of obese mice may 
contributed to the improvement of glucose intolerance. Besides, Rb1 treatment elevated 
circulation adiponectin, which has been indicated to ameliorate insulin resistance and reduced 
fatty acids levels in rodent, may contribute to the improved glucose tolerance and reduced fat 
accumulation we observed in the obese mice treated with this compound. Last, but not the least, 
we observed that Rb1 ameliorated hyperleptinemia, reduced the hypothalamic inflammation, 
PTP1B and SOCS3, improved central leptin signaling and restored central leptin sensitivity. 
 
Yizhen Wu                                                                                                                                                 95 
 
Hypothalamic inflammation is considered a key pathology of obesity in rodents and humans 
(Cai and Liu, 2012), leading to central leptin resistance through activation of the negative 
regulators of leptin signaling, SOCS and PTP1B (Milanski et al., 2012; Zhang et al., 2008). Our 
results demonstrate that Rb1 decreased the upregulation of SOCS3 and PTP1B in the 
hypothalamus of HFD-induced obese mice. Therefore, the inhibition of SOCS3 and PTP1B and 
attenuation of hypothalamic inflammation, contributes to the therapeutic effect of Rb1 on 
central leptin resistance observed in our mouse model. The improvement of hyperleptinemia, 
results from the reduction of fat mass, also contributes to the improvement of central leptin 
sensitivity. Overall, this study demonstrated chronic Rb1 treatment inhibited inflammation in 
the adipose tissue, liver, and the mediobasal hypothalamus of HFD-induced obese mice. Rb1 
treatment also resulted in the improvement of glucose tolerance, central leptin sensitivity and 
the hypothalamic leptin-pSTAT3 signaling. We also reported that Rb1 treatment increased 
circulating anorexigenic hormone PYY and regulated the melanocortin POMC/AgRP 
neuropeptides in the mediobasal hypothalamus, contributing to the negative energy balance. 
Therefore, ginsenoside Rb1 is a potential anti-obesity therapeutic agent by modulating obesity-
associated inflammation, improving central leptin sensitivity in the HFD-induced obesity. 
In chapter 3, we expended these findings to investigate the effect of chronic Rb1 treatment on 
leptin signaling and leptin-mediated BDNF regulation in the prefrontal cortex of high-saturated 
fat diet–induced obese mice. We found that Rb1 upregulated BDNF protein expression and 
corrected the impaired leptin-mediated BDNF regulation in the prefrontal cortex of obese mice. 
Furthermore, Rb1 improved hyperleptinemia and restored leptin sensitivity on the regulation of 
JAK2-STAT3 signaling in the prefrontal cortex of obese mice, by increasing these signal 
protein phosphorylation. Moreover, we used an in vitro cultural primary cortical neuron model, 
to evaluate the deleterious effect of saturated fatty acid, palmitic acid, on the leptin-mediated 
BDNF regulation, and the leptin-mediated neurite outgrowth and synaptogenesis; as well as 
investigate the treatment effect of Rb1 on the PA-pretreated cortical neurons. This study 
indicated that, in the cultured primary prefrontal cortical neurons, palmitic acid impaired the 
effect of leptin on BDNF, neurite outgrowth and synaptogenesis markers. Rb1 treatment 
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improved the leptin-mediated BDNF expression, leptin-mediated neurite outgrowth (branching 
and length) and synaptic proteins (SYN and PSD95) in palmitic acid pre-treated prefrontal 
cortical neurons.  
The present study demonstrated leptin elevates BDNF in the prefrontal cortex, as indicating by 
protein expression level in the in vivo study and immunochemistry and mRNA in the in vitro 
study. High-fat diet or palmitic acid altered the ability of leptin to elevates BDNF in the 
prefrontal cortex, suggesting that a high-saturated fat diet can affect leptin function in the 
prefrontal cortical neurons. These results are consistent with a previous report that demonstrated 
the impairment of central leptin-regulated BDNF in obese mice, which is associated with 
depressive behavior (Yamada et al., 2011). Moreover, mutation of the BDNF gene is associated 
with increasing early-onset obesity and cognitive impairment in BDNF-haploinsufficient 
patients (Gray et al., 2006). BDNF in the prefrontal cortex promotes neuronal plasticity and 
neurogenesis, which are important for learning and memory (Kanoski et al., 2007a; Sakata et 
al., 2013b). Thus, the impairment of leptin-regulated BDNF in the prefrontal cortex by saturated 
fat may play an important role in central nervous system dysfunction in obese subjects. The 
present study also demonstrated high-saturated diet substantially impaired leptin-JAK2-STAT3 
signaling in the prefrontal cortex of obese mice, suggesting central leptin insensitivity in obese 
mice. Central leptin insensitivity also exists in obese individuals. The prevalence of dementia 
and other neurodegenerative diseases was higher in obese subjects with hyperleptinemia 
(Carpenter et al., 2000; Carter et al., 2000; Lieb et al., 2009a), which suggests that high plasma 
leptin levels unlikely activate signaling pathways in the brain of obese individuals. Therefore, 
central leptin resistance is a pathology of obesity (Myers et al., 2008b). Leptin was shown to 
regulate neurite outgrowth (branching and elongation) and synaptogenesis (PSD95 and SYN) in 
the primary prefrontal cortical neurons in the present in vitro study. However, this ablility of 
leptin was blunt by palmitic acid, indicating saturated fat impaired leptin-mediated neurite 
outgrowth and synaptogenesis in cortical neurons. As prefrontal cortex is important for 
cognitive control (Cole et al., 2012b), and high-fat diet reduces synaptic plasticity in this region 
(Val-Laillet et al., 2011a) leading to learning and memory impairments (Laroche et al., 2000b). 
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Therefore, taken all together, the impairment of leptin-mediated BDNF expression and leptin-
JAK2-STAT3 signaling by saturated fat in the prefrontal cortical neurons may attribute to the 
impairment of leptin-mediated neurite outgrowth and synaptogenesis, and thus accelerate 
neurodegeneration and cognitive decline. Importantly, Rb1 treatment improved 
hyperleptinemia, improved leptin-mediated BDNF expression, as well as leptin-JAK2-STAT3 
signaling, which may facilitated to the improvements of leptin-mediated PSD95 and leptin-
mediated SYN, and thus improved neurite outgrowth and synaptogenesis. These results suggest 
that these effects of Rb1 may partly contribute to the improvement of cognitive function of 
ginseng treatment in a clinic trial (Heo et al., 2011). Therefore, Rb1 may have beneficial effects 
on obesity-associated neurodegenerative disorders.  
In chapter 4, we demonstrated chronic teasaponin treatment reduced obesity, hypothalamic 
inflammation, and central leptin resistance in high-fat diet-induced obese mice. Teasaponin 
treatment enhanced object recognition memory, and improved hypothalamic and cortical leptin-
JAK2-STAT3 signaling and cortical leptin-induced BDNF expression of HFD fed obese mice, 
as well as improved hyperleptinemia, hyperinsulinemia and glucose tolerance in obese mice. 
Moreover, teasaponin treatment ameliorated the impairment on leptin-mediated BDNF, leptin-
mediated neurite outgrowth (branching and elongation) caused by saturated-fat, palmitic acid. It 
is generally accepted that low-grade pro-inflammatory state is at the pathogenic core of obesity 
and type 2 diabetes. Therefore, teasaponin is a potential anti-obesity therapeutic agent that 
modulates obesity-induced inflammation and improves central leptin sensitivity in HFD-
induced obesity. Previously, both clinical and animal studies have shown that tea improves 
cognitive function (Kuriyama et al., 2006; Ng et al., 2008) and prevents impairments of learning 
and memory (Morton et al., 2005). Furthermore, tea increases brain activity in the prefrontal 
cortex of healthy volunteers as assessed by functional MRI methods (Borgwardt et al., 2012). 
Therefore, the effect of teasaponin, an active gradient of tea extract, on enhancing object 
recognition memory in obese mice, may contribute to the ability of tea to improve cognitive 
function and memory, and increase brain activation in the prefrontal cortex, as described 
previously (Borgwardt et al., 2012; Kuriyama et al., 2006; Ng et al., 2008). Cortical leptin 
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resistance was observed in the obese mice, while teasaponin treatment restored leptin 
sensitivity, illustrating by the improving of leptin-JAK2-STAT3 signaling in the prefrontal 
cortex of teasaponin-treated obese mice. It has been reported that leptin replacement improves 
cognition in leptin-deficient patients with a delay or decline of cognitive function (Paz-Filho et 
al., 2008). Therefore, teasaponin may improve recognition memory via attenuate HFD induced 
impairments of leptin signaling in the prefrontal cortex. 
It is known that BDNF-mediated synaptic plasticity is usually coordinated by the synaptogenic 
proteins, SYN and PSD-95 (Li and Keifer, 2012; Nelson et al., 2013; Robinet and Pellerin, 
2011; Wolkowitz et al.). Consistent with this, along with increased BDNF levels, our findings 
demonstrated that leptin stimulated SYN and PSD95 mRNA expression in vitro (Yu et al., 
2015). Furthermore, mRNA expression of the neurite outgrowth marker MAP2 increased in 
response to leptin in cultured prefrontal cortical neurons. It is well established that leptin has 
important effects on neurogenesis, synaptogenesis and dendritic morphology in the brain 
(Valerio et al., 2006; Yamada et al., 2011). Overall, these results suggest that leptin may 
promote neurogenesis and synaptic plasticity via increasing BDNF, SYN and PSD95 in cortical 
neurons. It has been reported that a diet high in saturated fatty acids induces neuronal 
degeneration and inactivates the leptin signaling molecule STAT3 in the hypothalamus of mice 
(McNay et al., 2012). This is consistent with our in vitro results, suggesting that saturated fatty 
acids also induce a leptin insensitivity effect on neurite outgrowth and synaptogenesis in the 
prefrontal cortical neurons. We also found that teasaponin reversed this adverse effect of 
palmitic acid on leptin-induced BDNF and neurite. It is known that the leptin signaling 
molecules, JAK2 and STAT3, are distributed around the postsynaptic sites in the cerebral cortex 
(Robinet and Pellerin, 2011). This suggests that teasaponin may modulate leptin signaling, 
BDNF expression and post-synaptic function in the prefrontal cortex, leading to improved 
recognition memory, suggesting the potential therapeutic effects on obesity-associated 
neurodegenerative diseases and cognition decline.  
Chronic treatment with triterpene saponins, i.e. ginsenoside Rb1 and teasaponin, in obese mice 
is effective in the anti-obesity, anti-obesity-associated peripheral and central inflammation, 
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improving hyperleptinemia and glucose intolerance, and correcting central leptin resistance, as 
well as improving hypothalamic and cortical leptin sensitivity. Those results are consistent with 
some of the clinic and animal data that ginseng or tea may act on anti-inflammation, anti-
obesity, and improve cognition (Borgwardt et al., 2012; Heo et al., 2011; Xiong et al., 2010). 
Ginsenoside Rb1 and teasaponin are triterpene saponin, belonging to steroidal saponins, which 
share structure features with steroid hormones (Attele et al., 1999a; Morikawa et al., 2006). Due 
to the steroid-like structure and the amphiphilic nature (Abid Ali Khan et al., 2012; Attele et al., 
1999a; Morikawa et al., 2006), ginsenosides Rb1 or teasaponin can intercalate into the plasma 
membrane replacing membrane cholesterol, which increases membrane fluidity and changes the 
immediate environment of cell membrane proteins, such as the GABA receptor (Abid Ali Khan 
et al., 2012; Attele et al., 1999a). Furthermore, ginsenoside may traverse cell membranes freely 
and activate intracellular membrane receptors, such as steroid receptors, which may regulate the 
transcription of target genes (Attele et al., 1999a). However, it remains to be determined if Rb1 
or teasaponin directly interacts with leptin receptor. 
Finally, both ginsenoside Rb1 and teasaponin ameliorated the impairment caused by palmitc 
acid on leptin-mediated neurite outgrowth and synaptogenesis in the primary cortical neurons. 
Besides, oral teasaponin has been demonstrated to improve recognitive memory. Taken all 
together, triterpene saponins (both ginsenoside Rb1 and teasaponin) have neuroprotective 
effects that can be potential therapeutic agents on treating obesity-associated neurodegenerative 
diseases. 
 
 
5.1.2 Proposed Mechanisms of Triterpene saponins in Overall discussion of findings 
Figure5.1 proposed the possible mechanisms of triterpene saponins (ginsenoside Rb1 and 
teasaponin) on treating obesity, obesity-associated inflammation and leptin resistance, as well as 
mechanisms of triterpene saponins (ginsenoside Rb1 or Teasaponin) on treating leptin 
insensitivity in the prefrontal cortex impaired by high-fat diet or high saturated fat, palmitic 
acid. 
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1. Long term maintaining mice on a high-fat diet containing saturated fat enlarges the 
adipocytes size and increases the proportion of large adipocytes in adipose tissue, causing fat 
deposition; as well as increases food intake and body weight gain, and thus becomes obese. Fat 
deposition increases the circulating leptin, contributes to the hyperleptinemia. During the 
obesity development, central inflammation plays a pathologic role, that increasing negative 
leptin regulator PTP1B and SOCS3 protein expression, and thus contributes to central leptin 
resistance and the impairment of leptin signaling (including pSTAT3, and pFOXO1) in the 
hypothalamus. Hyperinsulinemia exists in the obese mice. High-fat diet-induced obesity results 
in peripheral inflammation in liver and adipose tissue, which together with hyperinsulinemia, 
causes glucose intolerance. Peripheral inflammation, together with hyperleptinemia, also 
contributes to the peripheral leptin resistance. Importantly, chronic treatment the obese mice 
with ginsenoside Rb1 or teasaponin for three weeks, reduced food intake via increasing 
circulating anorexigenic hormone PYY expression and upregulation of anorexigenic 
neuropeptide POMC, as well as downregulation of orexigenic neuropeptide AgRP in 
mediobasal hypothalamus. Rb1 treatment also reduced body weight gain and adipocyte size and 
fat deposition, thus ameliorated obesity. Rb1 or teasaponin treatment reduced central 
inflammation and negative regulators (PTP1B and/ or SOCS3) of leptin signaling, then 
improved central leptin sensitivity. Rb1 treatment reduced peripheral inflammation in liver and 
adipose tissue, contributing to the improvement of glucose intolerance and peripheral leptin 
resistance. 
2. High-fat diet-induced obese mice developed hyperleptinemia and central leptin resistance in 
prefrontal cortex, which induced the downregulation of leptin-mediated BDNF protein 
expression. As BDNF is essential for the neurite outgrowth and synaptogenesis, therefore, high-
fat diet or high saturated fat caused the downregulation of leptin-mediated neurite outgrowth 
(MAP2) and synaptogenesis (PSD95 and SYN). Importantly, treatment with ginsenoside Rb1 or 
Teasaponin, ameliorated the impairment caused by high-fat diet or high saturated fat, improved 
leptin-pSTAT3 signaling, leptin-mediated BDNF, leptin-mediated neurite outgrowth (branching 
and elongation) and synaptogenesis in the prefrontal cortex. Thus, treatment with triterpene 
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saponins (ginsenoside Rb1 or Teasaponin) will potentially improve cognition and 
neurodegenerative disorders. 
 
 
  
Figure 5.1 Proposed mechanism of ginsenoside Rb1 treatment on obesity, obesity associated 
inflammation and leptin resistance; and proposed mechanism Rb1 or teasaponin improves 
cortical leptin sensitivity and synaptogensis in high-fat diet-induced obese mice. 
Abbreviation: HFD: high-fat diet; Rb1: ginsenoside Rb1; FI: food intake; BWG: body weight gain; PYY: 
peptide YY; POMC: Proopiomelanocortin; AgRP: Agouti gene-related peptide; PTP1B: Protein Tyrosine 
Phosphatase 1B; SOCS3: Suppressor of Cytokine Signaling 3; pSTAT3: Phosphorylated Signal 
Transducer and Activator of Transcription; pFOXO1: Phosphorylated Forkhead box protein O1; BDNF: 
brain-derived neurotrophic factor; MAP2: microtubule-associated protein 2; SYN: synaptophysin; 
PSD95: Protein Tyrosine Phosphatase 1B. 
 
5.1.3 Conclusions 
The results of present PhD thesis have been demonstrated the treatment effects of triterpene 
saponins (ginsenoside Rb1 and Teasaponin) on the high-fat diet-induced obese mice. All results 
are summarized in table 5.1, and proposed mechanisms are showed in Figure 5.1. 
In conclusions, food intake, body weight gain, fat deposition, hyperleptinemia, as well as 
glucose intolerance in the high-fat diet-induced obesity can be improved by chronic ginsenoside 
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Rb1 treatment. Obesity-associated peripheral inflammation and hypothalamic inflammation can 
be reduced by Rb1 treatment, indicating by the decrease expression of TNFα, IL-6, IL-1β and 
pIKK. Rb1 treatment also decreased the protein expression of SOCS3 and PTP1B, the negative 
regulators of leptin signaling. The reduced central inflammation and downregulation of SOCS3 
and PTP1B by Rb1 treatment, contributed to the improvement of central leptin resistance and 
restore leptin signaling in the mediobasal hypothalamus of obese mice treated with Rb1. 
Reduced peripheral inflammation contributed to the improvement of glucose intolerance. 
Besides, the increased expression of circulating PYY, and hypothalamic POMC upregulation 
and AgRP downregulation extend the mechanism on suppressing food intake by Rb1. Obesity 
impaired prefrontal cortex and induced leptin insensitivity in the cortical neuron in vivo and in 
vitro. Treated by the triterpene saponins, ginsenoside Rb1, leptin sensitivity in the prefrontal 
cortex of obese was improved, evidencing by the improvement of cortical leptin-JAK2-STAT3 
signaling, leptin-mediated BDNF expression, leptin-mediated neurite outgrowth (MAP2 mRNA, 
branching and neurite length) and synaptogenesis (PSD95 immunoreacitvity and mRNA). 
Teasaponin, the second triterpene saponin we tested, has been demonstrated that reducing food 
intake, body weight, improving hyperleptinemia and hyperinsulinemia, as well as improving 
glucose intolerance in the high-fat diet-induced obese mice. Chronic teasaponin treatment also 
decreased hypothalamic inflammation, improved central leptin resistance, and restored 
hypothalamic and prefrontal cortical leptin sensitivity via leptin-STAT3 signaling in obese mice. 
Using an in vitro prefrontal cortical model, we demonstrated that teasaponin treatment reversed 
the impairment by palmitic acid on the leptin-mediated BDNF expression and neurite outgrowth 
(branching and elongation). 
Taken all together, triterpene saponins, including ginsenoside Rb1 and teasaponin, have 
beneficial effects on anti-obesity, on treating obesity-associated leptin resistance, obesity-
associated inflammation, and obesity-associated neurodegenerative disorders. 
 
5.1.4 Recommendation for Future Research 
Based on the findings of the current series of studies, recommendation for future research are 
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listed as follows: 
1.  In the current study treatment of obese mice with Rb1 restored leptin induced activation of 
STAT3 phosphorylation, but not phosphorylation of FOXO1 in the mediobasal hypothalamus. 
Therefore, in the hypothalamus, Rb1 acted on the STAT3 signaling pathways rather than the 
FOXO1 pathway to restore leptin signaling and sensitivity. The precise mechanisms need 
further examination. 
2. In the current study, we demonstrated Rb1 elevated circulating PYY in the treated obese 
mice. PYY is a gut-brain anorexigenic hormone that promotes negative energy balance by 
reducing appetite (Boey et al., 2008). The increased plasma PYY in Rb1 treated obese mice may 
have contributed to the negative energy balance, lower body weight gain and fat accumulations 
in these animals. The mechanism by which Rb1 treatment increased circulating PYY levels 
requires to be further determined. 
3. This study demonstrated that Rb1 increased leptin sensitivity in the prefrontal cortex of obese 
mice, and in prefrontal cortical neurons treated with palmitic acid, as well as reversed the 
alterations of leptin downstream signaling molecules (pJAK2, STAT3, BDNF, and PSD95). 
However, further study needs to be carried out to determine if Rb1 directly interacts with the 
leptin receptor. 
4. This study illustrated that Rb1 treatment ameliorated alteration of leptin-JAK2-STAT3 and 
leptin-BDNF in the prefrontal cortex of obese mice and improves hyperleptinemia. Rb1 
treatment also promoted leptin’s effect on neurite branching and elongation, and synaptogenesis 
in prefrontal cortical neurons. As high-fat diet-induced obesity has been implicated in the 
progression of neurodegenerative diseases, such as vascular dementia. Rb1treatent may have 
therapeutic effects in attenuating the progression of cognitive declines in obese patients and 
reducing the risk of neurodegenerative diseases. This will be the next work to further validate 
using obese mice model. 
5. This study presented teasaponin improved leptin sensitivity in the prefrontal cortex of obese 
mice and primary cortical neurons treated with palmitic acid, and reversed the alterations of 
leptin downstream signaling. According to the amphiphilic nature and able to intercalated into 
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the plasma membrane, replacing membrane cholesterol and increasing membrane fluidity, and 
thus this molecule could change the immediate environment of cell membrane proteins. 
However, it is required to further investigate if teasaponin directly interacts with the leptin 
receptor. 
6. This study present oral teasaponin improved the recognition memory in treated obese mice. 
Since high fat diet-induced obesity has been implicated in the progression of neurodegenerative 
diseases, such as vascular dementia, teasaponin supplementation may have beneficial effects in 
attenuating the progression of cognitive decline in obese patients and reducing the risk of 
neurodegenerative diseases. However, the eventual toxicicity of long-lasting exposition to 
elevated concentrations of teasaponin should be examined before teasaponin supplementation to 
be recommended. 
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